n/a
full list rate price target
earn report pleas see tabl
launch coverag biopharmaceut industri posit
view univers large- smid-cap stock posit view driven
wane near-term concern drug price reform upsid evid strong
innov accommod regulatori
landscap modestli attract
valuat rel broader market host confer call et
feb dial-in us ou passcod
overweight-r name tilt toward higher-qu large-cap growth
narr domin commerci franchis improv margin rel
lower loss exclus loe risk smid-cap name near-launch
narr pipelin option neg turn sentiment merck
pt seem overdon us dont see keytruda threaten lung cancer
bristol dataset oper margin expans
signific pt bullish tirzepatid phase
data extend diabet franchis leverag start
kick pt eylea dupix
set exceed estim libtayo nsclc data provid attract
option pt think aducanumab alzheim diseas
get approv pt sotatercept data pulmonari
arteri hypertens pah open opportun model reblozyl
peak potenti appli therapeut pt like
combin launch galactosemia pivot diabet cardiomyopathi read-
signific option around ou right program
five equal weight-rat name bristol-my squibb pt
skeptic near-term opdivo lung kidney cancer dataset move
needl commerci posit pivot data dataset isnt
expect late pt strong skyrizi launch
price humira eros still loom could sever
street estim pt could see meaning eros
headwind off-set potenti kra data compel catalyst
omecamtiv tezepelumab pt abrocitinib data near-term
upsid risk dont see stock break without addit busi
develop ibranc data neurocrin bioscienc pt
near-term ingrezza headwind lack meaning clinic catalyst keep us
underweight-r name gilead scienc pt stock
appreci remdesivir coronaviru seem overdon us
pt doubt size commerci opportun across
gastrointestin eosinophil disord larg enough interest strateg player
particularli given competit headwind ahead de-risk data
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
summari rate price target earn estim report
barclay research share price target price shown primari list currenc ep estim shown report currenc
current fiscal year estim barclay research fiscal year estim barclay research
abbvie-allergan evolv
growth asset off-set humira eros
path revenu growth
late stage pipelin drive re-rat
fda approv aducanumab
drive share near term
seven launch contribut
endocrinolog franchis reach
updat across immunolog oncolog franchis drive increment valu
year
remdesivir coronaviru drive valu gilead
hiv franchis growth profil
filgotinib launch street expect
new pfizer look like
pipelin off-set
eylea eros curv look like
option valu libtayo nsclc data
sotatercept incorpor pah paradigm
reblozyl surpass consensu
infront mid-year updat de-risk
 demonstr proof concept
antolimab achiev consensu sale
fda approv base phase data
phase dbcm read-out posit
advanc phase asthma
phase data justifi move phase
pipelin de-risk
acceler path market could emerg
pipeline/platform drive valu
ingrezza sale exceed
pipelin drive increment valu
launch coverag biopharmaceut industri posit view
initi coverag large-/smid-cap name past month volatil
oscil wave price reform risk follow rel calm
improv perform polici gridlock ensu despit strong
perform biotech pharma still under-perform broader market figur
figur look balanc key driver competit dynam across
immuno-oncolog i/o space lung kidney cancer outcom aducanumab
submiss de-risk later-stag program across immunolog near-term drug
launch potenti headlin risk around drug price run-up elect
posit group whole think investor need
adopt stock-pick mental compani given vari exposur price
reform concern signific out-performance stock past six month
recent strong perform across sector biopharma compel top-lin
growth figur figur figur mind argu favor higher-qu
growth name without near- mid-term loss exclus loe risk
binari catalyst-driven name favor risk/reward across smid-cap space
prefer
later-stag stori
name evolv
de-risk
perform nbi vs
bloomberg barclay research
perform acq celgenelilli acq loxonew ceo start gilead aducanumab discontinu acq arrayabbvi acq allergangilead collab w/galapagosgrassley-wyeth fail spin upjohn mylan-combo acq otezlaimpeach startsaducanumab resurrect collab w/ beigenenovarti acq medicin companymerck acq arqulesanofi acq synthorxmerck announc women health biosimilar spin barclay biopharmaceut
absolut perform sector
look see differenti outlook across earn growth profil vs
broader market howev much appear driven low comp given industri
consolid show higher ep acquisit celgen
allergan respect look see biopharma middl
pack end key risk monitor run-up presidenti elect
whether investor use biopharma sourc fund avoid headlin risk around drug
price reform rotat happen run-up presidenti elect
biopharma under-perform market nbi/drg vs
industri start differ place term current price-to-earnings multipl
price reform remain loom risk space even dont expect legisl
progress
revenu ep growth scatterplot sector
revenu ep growth scatterplot sector
note pressur come despit evid drug price growth deceler
price actual figur figur howev polit drug
price reform like keep front-and-cent run-up elect given
bipartisan appeal pharma among industri lowest net
favor rate poll indic american consid current
level drug price unreason
net price fell
drug channel institut analysi ssr health data
kff health track poll adult conduct feb
bureau labor statist
net favor rate pharma all-tim
price price growthnet price gener think cost prescript drug barclay biopharmaceut
 heat mix defens innovation-focus deal
past year seen record amount biotech pharma deal
drive deploy capit unsurprisingli larger deal bristol-my
acquir celgen acquir allergan got much attent howev
also decent mix innovation-focus deal lly/loxo mrk/arql
rog/onc biib/nit past elect cycl saw dip
deal size strong year still activ calendar would expect similar dynam
play
global biotech pharma deal volum year
number global biotech pharma deal year
combin innov new drug class technolog continu de-risk
drug candid accommod fda power dynam
sector look fda approv see agenc remain activ even
high-watermark year importantli see sign trend revers
near term rather would argu potenti approv aducanumab
alzheim later year earli next could serv signal accommod
stanc toward neuroscience/neurodegener area stand stark contrast
fda mani success across oncolog
abbvi inc quarterli annual ep usd
consensu number bloomberg receiv gmt
initi coverag equal weight pt see balanc
risk/reward share stock sinc august vs nbi
alreadi price stronger contribut key growth asset consensu
forecast skyrizi alreadi sinc august
almost double-digit humira demand growth near term immedi
accret stand-alone pro forma ep estim inde
still think skyrizi psoriasi outperform guidanc
skyrizi/rinvoq rheumatoid arthriti like diminish impact stock
key near-term clinic catalyst across immunolog franchis crohn psoriat
arthriti atop dermat number alreadi competit
catalyst calquenc head-to-head data vs imbruvica bristol data
psoriasi could pressur narr around key asset abbvi
increas emphasi medium-stag pipelin make sens given larg
outsid street model skeptic see share accru
meaning valu de-risk phase data investor better clariti around
pace humira eros
humira revenu eros eight biosimilar entrant expect enter market
littl preced situat face model humira
sale peak steep declin follow
subsequ declin said remain signific error bar
around forecast estim vs consensu reflect
eros estim
expect upcom guidanc day updat ep guidanc
expect follow close allergan acquisit consensu clear cut
given varieti approach blend ep forecast combin abbvie-allergan
sit roughli line compani messag
accret first full year deal close forecast top-lin
revenu
valuat risk deriv price target base dcf analysi
wacc termin growth upsid risk price target includ acceler
skyrizi/rinvoq growth delay among humira biosimilar entrant de-risk
emerg new pipelin driver downsid risk includ delay allergan acquisit
close slower expect rinvoq growth new competit threat skyrizi
initi coverag equal weight price target
allergan acquisit expect close later quarter new
expect emerg larger better-diversifi resili compani
strengthen readi face impend humira adalimumab biosimilar
big part dynam howev growth compani key
driver imbruvica venclexta rinvoq skyrizi strong reflect
stock perform latter half estim key product
move higher result lack impact clinic catalyst view
arent alreadi address street number linger unknown magnitud
humira headwind start think difficult see multipl expand
even strong profil emerg near term inde
acknowledg stock trade meaning discount peer project
newco ep howev think that appropri level given humira
uncertainti next wave pipelin product whose commerci impact larg
weight
price target base dcf analysi wacc termin growth
impli price-to-earnings stand-alone ep reflect
balanc outlook growth asset though still biopharma peer given
loom patent cliff similar compani face trade
timingev catalystbarclay phase data rinvoq atop dermatitisw expect posit phase data support file later year launch induct data crohn also increment de-risk day call day rel short notic compani talk mid-lat stage pipielin navitoclax veliparib expect remain focal point top-lin phase data skyrizi psoriat arthriti crohn diseasew expect posit studi compel phase data howev focu drug safeti profil dose compani intend file competit efficaci profil dose rel dupix close allergan acquisitionupon close expect revis guidanc provid cover combin entiti expect minimum guidanc barclay potenti ep barclay earningskey focal point skyrizi rinvoq trend in-lin street rinvoq vs skyrizi vs pdufa date uterin fibroidsorilissa approv straightforward may also provid opportun discuss effort boost orilissa launch barclay biopharmaceut
what price
abbvie-allergan evolv
upon deal close near-term growth profil benefit improv optic
blend number even adjust growth profil still
compel inde expect current growth driver imbruvica venclexta
rinvoq skyrizi grow compound-annual-growth-rate
coupl continu growth humira competitor enter
market cost synergi allergan deal expect compani post
combin ep
there straightforward comparison given variabl street
model estim with/without allergan dont expect
complet reconcil deal close end new guidanc
issu could see dynam drag get closer earn
improv revenu ep outlook near term
develop pro-forma model better analyz profil combin
abbvie/allergan figur combin entiti see faster revenu ep growth
also perhap importantli smooth impact
humira biosimilar enter market
set emerg acquisit allergan signific debt balanc
sheet nevertheless even assum pay debt aggress
next three year plan still expect compani gener
cash flow period
current pro forma model forecast new earn
impli price-to-earnings multipl vs biopharma group trade ep
estim view discount appropri given number humira biosimilar
project enter market uncertainti pace magnitud
revenu eros well lack clariti next wave product beyond
current skyrizi rinvoq imbruvica venclexta
barclay research allergan cover barclay analyst balaji prasad
 standalonenewconewco revenu synergy- total cog cog cog gross sg sg sg sg total incom abbv incremental/newco minor interestebt tax net barclay biopharmaceut
growth asset off-set humira eros
partial expect growth skyrizi rinvoq imbruvica
venclexta off-set humira eros growth product
allergan portfolio cover increment bring total coverag humira
eros
what price
street forecast impli humira sale erod consist
reduct year absolut term street forecast humira
sale peak declin
push/pul eros growth offset
biosimilar threat humira franchis fret better half
decad howev time realli feel differ biosimilar
doorstep potenti eight compani launch figur
take aim like product face
potenti eros investor squar focus pace humira
eros whether compani current growth asset off-set eros
view humira eros faster anticip due number player
condens period launch import launch
reput within biosimilar space model eros
 off-set growth across growth product
ergan product time frame told expect make
project eros howev first year expect
optic look challeng shown figur
revenu contribut humira eros
guid oper growth humira impli sale
 street expect product reach
erod declin per year complic calculu
humira sheer magnitud revenu number sequenc entrant
rel short time period abil inabl suppli market
uncertainti whether biosimilar interchang
likelihood variou player take differ approach backdrop
think difficult argu favor higher estim
dont see experi neulasta/neupogen biosimilar
appropri comp note humira like largest opportun biosimilar
compani see keytruda/opdivo face competit later decad
see pressur compani get launch right take share reason
would argu greater annual averag declin model
declin year gain volum off-set loss humira share
decreas price follow gain volum share
price declin gain volum share price
driver see sale drop
adalimumab biosimilar expect launch
skyrizi lot potenti lot price compel
meaning outperform expect gate skyrizi sale
vs consensu time launch skyrizi benefit argument
favor better efficaci skyrizi recent best cosentyx head-to-head studi
vs cosentyx conveni dose vs entrant
weekli iqvia data suggest new prescript across dermatologist alreadi
match tremfya survey data show skyrizi almost par oral otezla
across front-lin agent figur figur
back trend provid guidanc skyrizi
view appropri conserv modestli vs
consensu given continu trend end tailwind
recent head-to-head data vs cosentyx lack competitor data across alreadi
approv agent impact market
look beyond howev see two key dynam watch
emerg competitor dataset might disrupt skyrizi less concern
 lilli mirikizumab believ could disrupt skyrizi front-
line posit put simpler term think program bristol oral
could pose bigger competit threat otezla offer modest
efficaci phase data bristol poetyk program expect set
potenti launch could dampen skyrizi psoriasi growth thereaft
addit indic skyrizi expect sale skyrizi driven
entir psoriasi indic though phase data psoriat arthriti mid-
keepsak initi phase data crohn diseas cd motiv
set drug label expans indic respect
also expect modest read-through pivot tremfya data crohn galaxi
expect later year note cautiou drug potenti
atop diseas atop dermat asthma exclud sale forecast
given lack de-risk data either indic agent
share new rx start psoriasi sept-nov
develop strategi skyrizi
factor mind forecast sale grow
bullish skyrizi potenti see de-risk
uc critic event given expect psoriasi market becom even
competit start
assign probabl success skyrizi driven de-risk data tremfya
psoriat arthriti think support toggl standard
phase asset henc crohn diseas assumpt ulcer coliti estim
reflect lack prior studi skyrizi popul final
mention earlier take conserv approach exclud atop dermat
asthma model given lack data support inhibit diseas
 launchcommentsbarclay data keepsak expect data motiv expect anticip file phase data may read-out plan barclay biopharmaceut
abbvi select inhibitor approv fall rheumatoid arthriti
ra make drug third jak inhibitor market ra pfizer xeljanz
lilli olumi notabl ahead gilead/galapagoss filgotinib initi script
trend encourag report sale somewhat disappoint
driven sampl market access didnt kick januari accord
surpris market develop slowli vs psoriasi given
medicar part channel play larger role level competit ra
access come on-lin earli januari begin see drug real demand
hereaft figur figur
similar skyrizi drug abil move beyond ra indic critic
drug meet outer-year estim posit phase data psoriat arthriti across two
studi disclos novemb februari surpris given xeljanz
show efficaci popul support snda submiss midyear
impli approv
import catalyst would argu
phase data pfizer abrocitinib atop dermat
rinvoq phase data atop dermat
approv price gilead filgotinib ra august
read-through filgotinib phase data uc
two atop dermat dataset highlight expect posit
would focus safeti profil agent see biggest
factor limit class set sign differenti abrocitinib
focus drug rapid efficaci itch compon diseas
phase rinvoq data demonstr compel efficaci data though unclear
dose ultim file import view high-
dose data differenti vs dupix efficaci
share new rx start ra sept-nov
competit threat gilead filgotinib unclear given entrench posit
marketplac lack differenti two agent said gilead
price strategi could impact landscap separ also see filgotinib phase
data uc de-risk rinvoq phase data
factor mind forecast rinvoq sale grow
vs consensu respect
street overal jak adopt given competit
jak mechan expect ultim fare better
 launchcommentsbarclay po rhematoid phase data dose file compar efficaci filgotinib data barclay biopharmaceut
imbruvica venclexta heme-onc
imbruvica continu grow robust clip y/i even eclips
run-rat dont see anyth disrupt dynam near term
greater adopt combin venclexta earlier cours treatment could
drive durat longer though patient abl toler combo
increment benefit durat take coupl year materi
incom statement given dynam modestli street near
term conserv beyond
one key trial watch elevate-rr studi calquenc vs imbruvica expect
read could provid rational start calquenc imbruvica howev
dont think much counter imbruvica venetoclax combin
dont expect patient current imbruvica switch therapi due data rather
see data best case impact new patient result see minim
impact data estim
model sale imbruvica vs consensu
venclexta vs consensu see product achiev sale
help off-set eros humira longer term model combin sale
ahead imbruvica loe
price target share base dcf analysi assum wacc
moder conserv bloomberg report wacc roughli in-lin wacc
past six month termin growth in-lin standard assumpt
larg biopharma declin revenu termin valu year also appli
long-term tax rate altogeth price target impli price-to-earnings ep
reflect balanc outlook growth asset though still
biopharma peer given loom patent cliff similar compani face
trade
risk price target
upsid risk thesi hiccup biosimilar humira launch greater synergi
realiz allergan integr clinic commerci setback
competitor gilead filgotinib abrocitinib astrazeneca calquenc
acceler clinic timelin key indic
downsid risk thesi clinic trial setback limit expans key product
new indic skyrizi ibd ad poor payor access face biosimilar
brand competitor failur consumm allergan transact
amgen inc quarterli annual ep usd
consensu number bloomberg receiv gmt
initi coverag equal weight pt acquisit
otezla celgen provid boost revenu lower potenti
anoth year revenu howev otezla modestli improv
profil still biopharma peer compound-annual-growth-rate vs amgen late-
stage pipelin among intrigu across larg biotech less like support
multipl expans kra inhibitor tezepelumab asthma
alreadi street model though data omecamtiv heart failur later year could
notabl chang calculu like program likelihood success data
particularli given peak sale potenti rel low street expect
potenti data could provid visibl file strategi near-
term ultim see intens competit across kra space limit
updat mirati johnson johnson kra program weight
see balanc risk/reward tezepelumab given high expect drug
recapitul impress phase impact exacerb irrespect eosinophil
legaci headwind persist feel brunt overal concern
meet exceed guidanc consist conserv
new cfo like even reason set easi bar model sale
toward top-end guidanc larg in-lin street guid
consensu said see number notabl headwind
may weigh sentiment like keep compani rais top-end
guidanc call expect notabl growth contribut fy otezla
prolia y/i xgeva y/i biosimilar y/i
valuat risk assign price target base npv sum-of-the-part
analysi compris commercial-stag portfolio biosimilar pipelin
net cash inclus beigen stake risk includ faster eros
biosimilar pronounc competit key commerci driver advers ip proceed
clinic trial setback key program omecamtiv tezepelumab
initi equal weight price target
improv product aggress polici return capit
sharehold free cash flow help compani outperform
sector despit headwind legaci product eros
alon modest contribut recent launch opportunist acquisit
otezla provid boost top-lin growth y/i help
per year though growth outlook period still tepid vs
peer revenu compound-annual-growth-rate vs ep
price-to-earnings multipl ep touch peer
focu late stage pipelin catalyst
inde challeng return sustain mid-singl digit growth
lack recent needle-mov launch hasnt launch product gener
sale sinc prolia/xgeva late stage pipelin could counter
pivot dataset read address multi-billion dollar market
lung cancer tezepelumab asthma omecamtiv heart failur howev
tezepelumab alreadi street model face competit
commerci question think multipl expans current level
challeng omecamtiv could chang narr given low street expect
sale potenti orthogon mechan action approach
in-lin past practic set multipl beat rais provid
conserv initi guidanc also understand given new cfo first
guid given dynam model toward high-end revenu guidanc
barclay vs guidanc notabl ep vs
pt base npv sum-of-the-part analysi compris contribut
market product select pipelin asset beigen stake net cash model
discount rate consist methodolog mega-cap biopharma compani
risk includ faster eros pronounc competit key commerci driver
advers ip proceed clinic trial setback key program
legaci enbrel sensipar g-csf esa recent launch includ repatha aimovig parsabiv even
timingev catalystbarclay interim analysistop-lin data phase galact studi heart failur hfref data expect read-out ye posit bias data like compar entresto risk reduct adempa data present march phase data hle bite bcma top-lin data navig phase asthma studyamgen intend share data meaning dataset given skeptic alreadi around competit profil rel bcma agent timelin push view neg tezepelumab phase data posit given compel phase data key queestion drug reduct exacerb rate irrespect eosinophil count hold gener speak data high eosinophil subgroup compar dupix phase nsclc data potenti esmo septemb updat phase datasetsw expect studi stop interim analysi given high-bar superior superior stat sig time cv death expect data compani specif around time sequenc data updat think worst updat phase data present durabl respons sign efficaci tumor close watch amgen recent complet enrol phase nsclc monotherapi studi data expect follow-up data patient avail expect drug show efficaci though key focu comparison mirati player barclay biopharmaceut
path revenu growth
least organ acquisit otezla reset revenu base
boost growth profil compound-annual-growth-rate
howev profil still look tepid broader biopharma index notabl lower
higher-multipl peer broad peer set vs lly/regn/mrk inde legaci
product eros wont sever remain
signific persist headwind eros respect
growth contribut across key driver compound-annual-growth-rate otezla repatha
aimovig biosimilar arent enough fill remain gap
get compani annual growth peer
backdrop believ stabl base busi multipl expans
pipeline-driven key data readout
what price
consensu impli growth follow y/i top-lin compound-annual-growth-rate growth
legaci product enbrel neupogen/neulasta aranesp/epogen sensipar
made half total product sale declin
contribut significantli declin top-lin revenu
even consid growth product
compani set begin year top-lin compani exist growth
product would off-set henc top-lin compound-annual-growth-rate howev there still
hole revenu line compani match profil higher-
forecast enbrel sale declin rise
print benefit higher net sell price low singl digit account
adjust estim benefit without benefit one-tim
adjust net sell price like flat project limit benefit
call project demand declin forecast sale vs
consensu forecast compound-annual-growth-rate
forecast inform factor recent demand trend evidenc
report sequenti declin
report declin market share across rheumatoid arthriti ra psoriat arthriti
ankylos spondyl accord brandimpact figur increment
pressur first full year competit skyrizi pso rinvoq ra
addit launch expect gilead filgotinib ra jnj tremfya
chang enbrel market share
peak around rise competitor follow neulasta
biosimilar continu declin impact eros larg alreadi
play neulasta face steep declin drop run-rat
neulasta onpro help hold share peak
long-act segment start show crack defens strategi franchis
share fall sequenti given dynam coupl recent launch
yet anoth competitor late sandoz ziextenzo expect continu declin
model neulasta sale declin compound-annual-growth-rate
note neulasta print like face challeng optic barclay vs consensu
given difficult comp neulasta sale
esa dynam set continu competit price pressur
amgen esa erythropoietin stimul agent franchis anemia peak
period declin thereaft driven primarili lower util epogen
freseniu facil lower price facil biosimilar competit lesser
extent lower demand aranesp dynam expect revers
introduct agent
bristol/acceleron reblozyl neg impact demand trend expect
mid-teen eros trend seen epogen continu
intensifi model compound-annual-growth-rate
anemia
like acquisit otezla remov neg optic around declin top-
line also gave compani chanc leverag exist infrastructur
relationship around enbrel expect otezla continu grow see uniqu
posit psoriasi oral option howev real strateg import view
bridg period later-stag pipelin may provid next wave
growth asset
forecast sale compound-annual-growth-rate estim
take account increment leverag product hand
increment gain label expans behet late scalp psoriasi
off-set increment pressur new competit inhibitor
beyond factor highlight note on-going litig otezla ip
markman hear recent held amgen sandoz expect
develop front provid headlin risk share year
ultim concern expect signific due dilig conduct
given price tag base case assum gener entri summer
illustr earlier settlement would drive npv everi year cede
impact pt year gener otezla entri
aimovig race first anti-cgrp antibodi migrain prevent debut
market may quickli upend entranc eli lilli emgal
teva ajovi follow septemb class continu grow impress
aimovig ultim lost share combin free-drug program constip
side effect strong execut lilli think cgrp market ampl room
grow prophylact use still remain low aimovig benefit
somewhat think get complic expect approv
launch data readout oral option acut prophylact
begin make headway market oral vs inject iv/subq data
similarli favor wed expect oral win modestli consensu
think take meaning out-performance clear visibl
aimovig reach sale drive meaning multipl expans
repatha second chanc lower price
repatha direct monoclon antibodi approv fda
treatment hypercholesterolemia high low-dens lipoprotein cholesterol despit
compel clinic data reduct passabl clinic outcom data massiv
method cyrstallin method method method method method cyrstallin composit method use method barclay biopharmaceut
patient popul impact sale class disappoint given access hurdl
patient afford taken multipl action address constraint
step-down sell price earli mean need grow volum
off-set price think move help dont expect sale break
forecast sale vs consensu expect
pressur outer year novartiss inclisiran esperion bempedo acid
leverag strong brand equiti biolog space launch
biosimilar line product less two year portfolio alreadi approach
run-rat think potenti exceed middl decad
wed expect cadenc revenu per biosimilar peak earlier life cycl
addit potenti biosimilar make entranc suspect compani first
five launch amgevita kanjinto mvasi avsol like go better
biosimilar soliri eylea nevertheless repres fast grow sourc
revenu compani exist
late stage pipelin drive re-rat
potenti though think that like depend upon omecamtiv
tezepelumab clinic data pivot data three asset expect
potenti set launch three product meaning
sale start less debat commerci perform expect de-
risk pipelin percept commerci opportun face asset
drive share perform front excit omecamtiv given
magnitud commerci opportun strength phase data low
street expect contrast tezepelumab wide expect
posit data later year alreadi bake street model
market think
pipelin attent skew toward tezepelumab estim
bake street model alreadi drive much perform
last year
omecamtiv mecarbil novel inotrop agent develop treatment patient
heart failur hf reduc eject fraction hfref given impair
myocardi contractil central event progress diseas patient
increas forc contract long sought-aft intervent strategi
inotrop use acut clear benefici effect
hemodynam paramet increas cardiac output long-term use inotrop
howev limit underli mechan modul calcium ion
balanc flux drive calcium overload manifest increas heart rate
vasodil larg phase studi agent either demonstr benefit
worsen morbid mortal contrast omecamtiv inotrop effect direct
activ sarcomer rather modul calcium gradient
comprehens phase phase program span trial
particip view clear mechanist differenti omecamtiv prior
inotrop demonstr well evid improv hemodynam
paramet without commonli associ side effect
effect omecamtiv demonstr phase cosmic-hf studi
galactic-hf readout expect
base point initi galactic-hf phase studi
omecamtiv vs placebo studi design power detect
risk reduct cv death interim analys built studi
one-third two-third target cv death reach first interim reach
march studi continu without modif second expect
conduct later final read-out expect dont anticip
studi stop superior given high-bar defin stop studi
statist signific primari endpoint well statist signific
secondari endpoint time cv death nevertheless posit bias
ultim outcom assign probabl success given strength phase
data increment de-risk studi stop due safeti
soc standard
heart failur affect us expect grow affect close
hfref account roughli half market limit option beyond combin
diuret angiotensin system blocker beta-block entresto sacubitril plu
valsartan quickli gain share sale alreadi run-rat ww
us mortal rate still remain high
assum omecamtiv post risk reduct top current standard care
think omecamtiv match entresto impli share peak hfref
model launch meaning sale essenti begin model in-
line price entresto launch drive peak sale estim us
econom interest ou sale servier conserv exclud
model base assumpt calcul npv omecamtiv sale
po exclud potenti mileston
comparison baselin data hfref studi
american colleg cardiolog ace angiotensin-convert enzym inhibitor af/f atrial fibriliation/flutt arb angiotensin receptor blocker cv
cardiovascular hhf hospit heart failur hr hazard ratio lvef left ventricular eject fraction nyha new york heart associ rr risk reduct
entrestofarxigavericiguatomecamtiv arti astrazeneca merck bayer cardiac mysoin activatorstudyparadigm-hfdapa-hfvictoriagalactic-hfstudi mean enrol treat popul entresto-tr patient farxiga-tr patient patient patient lvef lvef class criterianyha class ii-ivnyha class ii-ivnyha class ii-ivnyha class ii-ivclass ii iv af/f hhf arb vs enalaprilfarxiga vs placebovericiguat vs placeboomecamtiv vs bid vs qd placebotitr placebotitr max bid placeboprimari endpointcomposit hhf cv deathcomposit hhf cv deathcomposit hhf cv deathcomposit hhf cv deathresultscomposit hhf cv death vs hr vs hr top-lin reduc risk compositecv vs hr vs hr vs hr vs hr late-break march interim databnp nt-probnp pg/ml barclay biopharmaceut
project sale growth entresto
tezepelumab monoclon antibodi target tslp thymic stromal lymphopoietin
cytokin believ central regul mediat inflamm drug
co-develop astrazeneca book us sale astrazeneca ou phase data
sever asthma demonstr compel reduct annual rate exacerb
irrespect eosinophil data high eosinophil cohort in-lin better
dupix low eosinophil cohort look meaning better eosinophil cut
dont match exactli tezepelumab studi didnt clear dose respons
data highli impress regardless
phase program on-going pivot navig inhal corticoid steroid user
expect read support file thereaft addit studi also
underway would support life cycl tezepelumab sourc oral corticoid steroid
user path-hom pre-fil syringe/autoinjector/at-hom administr
look commerci opportun sever asthma see larger grow market
accommod dupix tezepelumab howev tezepelumab
overcom dupix year head start think demonstr follow
recapitul phase efficaci data irrespect eosinophil level
impress piec tezepelumab data highli differenti vs dupix
tezepelumab
high eosinophil cohort
demonstr benefit lowest cohort think would highli competit
demonstr clinic relev level efficaci atop dermat atop
diseas ad asthma nasal polyp high degre overlap dupix
benefit clinician payor abl address multipl diseas
safeti must continu hold incid discontinu rate
larg similar tezepelumab placebo event larg benign long
new/unexpect safeti event increas incid occur think would
add competit efficaci recapitul
forecast dupix gener asthma revenu think
tezepelumab could match figur particularli recapitul phase data
low eosinophil subgroup assign po program calcul npv
per share
comparison tezepelumab phase data relev dupix data set
 equival respect unit use studi aer asthma exacerb rate pbo placebo everi week everi week
oral small molecul inhibitor specif kra mutat kra
driver non-smal lung cancer nsclc frequenc colorect cancer
prior kra larg view undrugg target
subsequ advanc understand protein structur allow target
small molecul first move clinic back
understand report respons rate nsclc patient
target dose back later
updat data move phase potenti registr monotherapi studi
nsclc stori howev complic disappoint initi clinic data
colorect cancer emerg variou competitor well notabl
expect like first kra inhibitor approv howev
uncertainti around number factor make difficult ascrib aggress revenu
estim includ durabl respons number competitor
like split market like import combin approach
disappoint initi monotherapi data think drug market potenti
could benefit revenu number see competit space
increas like temper enthusiasm around commerci opportun
low-dos rate asthma exacerb wk reduct vs eosinophil count eos/l annual reduct vs eos/l annual reduct vs annual reduct vs annual reduct vs annual reduct vs fenofeno reduct vs reduct vs reduct vs reduct vs reduct vs phase quest dose tezepelumab phase dose barclay biopharmaceut
nsclc data earli data look compar across
initi phase data demonstr clear efficaci monotherapi
orr dose subsequ enrol addit patient saw
respons rate drop dose though drug achiev
diseas control rate limit follow-up median dose week
made difficult draw conclus around durat respons data report
mirati later appear roughli compar orr across nsclc
patient similar depth respons mirati highlight potenti
tissu distribut
remain unclear whether drive meaning
differenti term clinic activ nsclc
amgen potenti pivot phase studi rapidli complet enrol
data anticip year patient complet least six month follow-up
though timelin tight late-breaker/present wouldnt surpris
get minimum top-lin updat around meet may
think good sens respons rate calcul
six month last patient enrol decemb ultim think esmo sept
like venu full readout
beyond look well track updat phase monotherapi
studi particularli hand patient pr sd could approach
cutoff use april status/progress treatment-
nave patient enrol phase monotherapi top-lin keytruda combo
data broader combin studi updat keytruda mek present earnest
later year also commun plan publish phase monotherapi
studi updat data year
statusnext updatephas enrol treatment-nav patient last updat esmo/wclc orr asco phase potenti pivot enrol completeddata esmo file w/keytrudaongoinginiti data w/mek inhibitorenrollinginiti data updatephas addit patient last updat esmo orr w/mek inhibitorenrollinginiti data updatephas tumorscolorect cancernon-smal cell lung cancer barclay biopharmaceut
comparison clinic profil
base comparison phase monotherapi dataset
acknowledg limit small number limit follow-up cross-trial
comparison look better posit best-in-class narrowli nsclc
wider margin said continu enrol patient
monotherapi phase trial may suggest higher dose began show better
data area close watch
size opportun
kra mutat found predominantli nsclc mcrc make
case respect impli potenti address incid popul
nsclc mcrc us eu respect
given like readout later year on-going potenti pivot phase
monotherapi studi could see file fda ye posit
launch tangibl sale begin model first
kra market nsclc peak market share assum net price
drugcompanycombin nsclc pan-egfr nsclc egfr nsclc -meet fda discuss potenti regulatori strategy-wil initi five combin trial initi phase studi expect arax -- phase start juli data nsclc egfr start decemb pr esmo diarrhea anemia common one diarrhea nausea anemai decreas gr fatigu decreas appetit dyspnea common diarrhea nausea ast increas vomit fatigu barclay biopharmaceut
arriv us sale less convinc
competit model peak us share translat us sale approach
eu assum discount us price one-year delay launch
peak share nsclc respect total sale
time frame addit opportun cancer given
lack de-risk data competit leav upsid model
share demonstr solid perform in-lin broader nbi
index vs nbi owe enthusiasm around opportunist
acquisit otezla repeat beat rais
pt base npv sum-of-the-part analysi driven market product
biosimilar select pipelin asset net cash
tax assign long-term tax rate
discount rate model wacc base standard assumpt mega-cap
biopharma compani fall in-lin report wacc bloomberg
share count valuat assum end dilut share outstand
risk rate price
upsid risk valuat includ slower/limit uptak gener biosimilar
launch mid-year guidanc updat above-rang current consensu galactic-
hf omecamtiv stop earli success due posit interim analysi
downsid risk valuat includ faster eros biosimilars/gener
increas competit poor payor access key franchis advers ip/leg
decis clinic trial setback
biogen inc quarterli annual ep usd
consensu number bloomberg receiv gmt
initi coverag overweight price target much like
perform year dictat prospect aducanumab approv
alzheim diseas ad view clear expect approv given neg
investor around program would argu upside/downsid skew
posit acknowledg there plenti fda take issu across phase
analys hearsay commentari fda support file doesnt necessarili tip
hand approv help think compel enough argument
effect seen higher doses/long exposur particularli context unmet need
ad lack option like approv next five year fda thu
far unabl move needl fight ad given massiv econom
driver million patient estim net price access
medicar zero competit near-term support peak estim
net impact share price could consider
expect continu volatil around timelin aducanumab assum bla file
goe end in-lin guidanc expect volatil share around prioriti
vs standard review decis may time-frame advisori committe meet
september/decemb priority/standard despit hot spot otherwis expect share
gradual move higher balanc year potenti pdufa date
background new competit spinraza legal headwind tecfidera
roche/ptc risdiplam approv pdufa may straightforward expect
intensifi competit pressur spinraza immedi particularli
roch like aggress lower price spinraza growth alreadi moder
downturn could signific notabl street sale
vs vs though expect drug
hold better ou given timelin access/reimburs tecfidera win
help put floor valuat base busi though addit
case summer could see concern resurfac vumer launch slow start
expect expect get pass expect investor
look see pickup next year
valuat risk assign price target base npv sum-of-the-part
analysi compris tecfidera/vumer rest ms franchis
net cash addit ionis/samsung jv stake total
revenu risk includ primarili neg outcom regardin
aducanumab approv near-term gener tecfidera entrant faster eros spinraza
initi coverag overweight rate pt
goe aducanumab prospect approv goe stock despit competitor
challeng commerci product spinraza tecfidera street
valu base busi commerci product royalti cash ex-pipelin
provid floor valuat discuss aducanumab
pipelin think compel asset pipelin lupu al
ophthalmolog warrant valu also believ street larg ignor
aducanumab play mind think current share price bake
aducanumab acknowledg likeley undershoot dcf
valuat neg aducanumab outcom regress price-to-earnings multipl in-lin
rang growth challeng compani loe risk valuat ep
impli around similarli posit scenario expect investor focu
price-to-earnings multipl approach particularli given likley generalist interest would
result backdrop dont think unreason stock could trade
turn ahead peer turn current valuat impli
base roughli see upsid downsid fda
decis base curren share price today
bullish aducanumab prospect approv
drawback mix phase result engage/emerg studi
obviou easili enumer dont think would posit fda
hadnt seen merit revis analys around higher doses/high exposur
backdrop unmet need patient base expect highli vocal
process dont see refut issu data rather
provid argument favor benefit put bluntli less make best
argument rather provid argument that credibl anticip volatil around
accept bla heighten around adcom ultim expect
share gradual move higher specialist generalist look exposur
potenti approv ad
upon approv believ aducanumab could valu dcf
upsid around potenti approv ad decidedli compel even
payment owe eisai consider commerci invest sale forecast
aducanumab wide varianc assum model would
impli add unit state assign probabl approv europ
size ou market opportun complex think upon visibl
approv ex-u opportun could add anoth po
sensit analysi aducanumab po discount rate
probabl successdiscount rateassetpo valuep sharemultipl product valu platform valu barclay biopharmaceut
timingev catalystbarclay pdufaw expect approv expect favor dataset given strength phase data repres first major readout nightstar phase choroideremia readoutunderappreci catalyst phase show better access antibodi cinpanemab phase parkinson readoutrisdiplam approvalw expect sma type launch follow shortli thereaft see signific impact share approv wide expect expect reaction driven q/q sale impact aducanumab adcomw would expect fda hold advisori committe meet anticip panelist discuss contenti ultim support approv aducanumab bla filingw expect on-schedul file aducanumab bla acceptedw expect bla accept anticip standard review grant prioriti review would posit receiv read-through accommod fda barclay biopharmaceut
fda approv aducanumab
ye think think display suffici data explan
phase program reason file aducanumab approv sentiment share fda
repeatedli highlight acknowledg inde uphil
battl continu make case aducanumab particularli given mix phase result
one fail engag one didnt emerg studi drawback
what price
street pretti split aducanumab approv reverse-engin model
estim share current price aducanumab
announc discontinu emerg engag phase studi
aducanumab futil last year march reviv program seven month later
octob follow post hoc analys larger arguabl complet dataset
higher dose patient well discuss fda
latter think street nonetheless continu labori debat
data unveil date would backdrop commentari
convers fda agenc found reason file data
would agre made convinc argument detail
futil analys flaw prematur given protocol amend skewed/ limit
patient sampl henc look larger dataset togeth popul
would appropri analysi ultim would suggest higher dose
higher exposur aducanumab effect approach slow clinic declin
hindsight approach futil analysi flaw pool studi
data without censor protocol chang name protocol version
reflect updat learn intend real-world use implement march
allow carrier titrat max dose vs follow
updat prime find demonstr reduct aria incid sever
dose titrat instead futil analysi captur disproportion patient mix
proport patient receiv low vs high dose aria-rel dose
month follow engag fda conduct post-mortem
wherein subsequ post hoc analys show signific larger patient dataset
includ patient exclud futil cutoff decemb
reach week complet treatment period over-the-counter opportun
complet patient emerg engag time
studi discontinu march well patient thereaft
larger dataset high dose
total patient analysi larger dataset figur high-dos aducanumab lower
clinic declin measur cognit function primary/secondari endpoint
emerg studi though fail engag studi note
longitudin analys kol found magnitud effect noteworthi
cdr-sb placebo pet subpopul studi low- high-dos
amyloid pet suvr nomin statist
signific emerg see greater effect correl greater median
engag note miss larg due enrol time begun
month emerg enrol patient time implement
led greater low-dos popul less patient complet full high-dos
cours dose
analysi unfortun yet provid secondari endpoint analys
popul though comment consist find
cdr-sb primari see stark differ
popul similar across emerg engag suggest
credibl statist exercis demonstr effect
aducanumab higher dose
p-valu nomin intent treat protocol version bl baselin longitudin chang baselin
find detail think make compel argument favor
approv regulatori agenc seem worst open discuss best
support acknowledg fda support aducanumab bla submiss
doesnt necessarili support approv howev encourag fda
consult throughout new analys fda also support decis
begin re-dos studi agenc go ultim nix bla due lack two
well-control phase demonstr clinic benefit dont think biogen
would move forward
global estim alzheim diseas us
increas preval get older popul cur disease-
modifi treatment avail clinic effort focu symptom behaviour
aducanumab expect first disease-alt therapi come market
meaning advantag shape treatment paradigm captur
signific share also develop assay aid diagnosi patient
wed expect pool elig patient grow payer/mco access continu
dose itt dose dose itthigh dose dose itt dose dose itthigh dose week week pet suvr bl barclay biopharmaceut
debat gener wed expect aducanumab gain broad coverag medicar
popul key demograph onset
assum launch next year estim unadjust sale
trend though current exclud ou valuat
clariti around ou regulatori path remain unclear model
ou opportun assum launch project sale
estim peak ou penetr total global market opportun
assign po translat npv per share
alzheim diseas preval diagnosi aducanumab market net annual wac annual discount aducanumab sale us alzheim diseas preval diagnosi aducanumab market net annual aducanumab sale ou mn barclay biopharmaceut
estim vs street model think competit spinraza
risdiplam remain vastli underappreci street consensu model
modest impact outer-year dose dynam spinraza alreadi slow growth
 suspect risdiplam introduct mid-year drive eros
intensifi expect ou sale somewhat resili
though consensu estim come recent month street still model
modest compound-annual-growth-rate declin five year consensu
fall
weve seen slow patient therapi q/q figur spinraza posit
sma paradigm yet palpabl shift one novartiss zolgensma launch
last year yet make real impact spinraza sale rather look roch
launch risdiplam partner pdufa may later year bigger threat
spinraza nonetheless dont think street yet fulli bake immin
threat outer-year spinraza number still remain high view seen
recent downward revis latter part last year though street remain
optimist consensu model five-year compound-annual-growth-rate
consensu spinraza
solid long-term data attest spinraza durabl argument
small sampl size high inter-pati variabl fair dont think
enough withstand roch entranc particularli risdiplam offer clear conveni
benefit oral vs intrathec without efficaci drawback rather data date appear as-
good better metric spinraza
zolgensma data as-good better cur potenti gene therapi
howev less concern threat novarti see zolgensma
posit incid popul appropri younger sever type
patient type ii/iii patient surviv rate better-to-norm henc less like
seek gene therapi access limit given price tag still evolv
payer landscap gene therapi
net preval popul exist patient may seek gene therapi atop
incid popul slow new q/q patient add dynam even
assum spinraza achiev ww peak sale year
declin next year eros acceler thereaft
compound-annual-growth-rate vs expect segment realiz brunt eros
figur figur
risdiplam zolgensma data improv upon spinraza
zolgensma clear choic type
across type dataset risdiplam zolgensma clear clear
improv seen spinraza obviou pushback
small sampl size compar spinraza endear firefish part
 part rel high inter-pati variabl vari time measur
howev rate magnitud improv difficult disput exampl
event-fre surviv ef rate zolgensma risdiplam perform better
spinraza zolgensma risdiplam
spinraza year
separ motor mileston zolgensma expectedli better popul
although risidplam also fare better spinraza sit without support
 stand
ultim think type patient treat zolgensma follow
mainten risdiplam spinraza dynam expect risdiplam win
risdiplam conveni type
analys across type segment less straightforward heterogen
differ endpoint although net-net think risdiplam data still
encourag spinraza despit recent sunfish part data suggest lower-than-
expect magnitud benefit like owe broad heterogen patient
enrol zolgensma data rel less compel type moreov
emphas adult segment later-onset type continu key growth
driver spinraza make new-start alon certainli could
testament spinraza convinc util popul howev think
indic increas demand later-onset patient rel
less sever type better-to-norm surviv rate patient easili
low-hang fruit would preferenti conveni offer risdiplam
complet think favor ipr decis earlier month meaning
clear event share two addit court case still remain decid
tecfidera ipr certainli domin overhang share leav
investor sidelin even spite believ high likelihood
aducanumab approv unconcern remain court case see biogen
well-posit maintain ms stabil make headway switch patient
vumer
what price
share larg written tecfidera outer-year valu lead
ipr decis seen much return estim drive valu today
earlier month patent trial appeal board ptab hand much
need victori tecfidera franchis rule claim
unpatent larg view import clear event news sent
share high vs nbi
howev fall backdrop still-ongo case delawar multipl
parti west virginia expect decis around mid-
year delawar case held trial decemb west virginia held februari
parallel appeal decis delawar court find banner life
scienc infring patent expiri june expect
appeal ipr decis
broadli speak increasingli less concern gener risk tecfidera see
viabl path forward continu leverag franchis cash flow
suffici manag switch vumer expiri moreov dont
expect at-risk launch tabl look g-tecfidera launch toward
announc settlement sever filer entranc ahead
larg part vumer launch defens strategi maintain stabil
ms portfolio particularli tecfidera/fumar segment made
ms sale total revenu last year
inde efficaci demonstr open-label studi mean
reduct gd lesion reduct patient respect
newli diagnos key differenti toler gi safeti profil
clinician posit tecfidera gi issu usual manag typic
occur start treatment almost ultim discontinu
vumer tecfidera head-to-head studi tecfidera
patient vumer experienc fewer day intens score igisi
measur individu gastrointestin symptom impact scale adjust rate ratio
igisi self-assess scale intens durat
key gi symptom nausea vomit upper/low abdomin pain diarrhea
moreov tecfidera vumer patient lower discontinu rate due gi
vs fewer day igisi score rr rr less
impact gi symptom daili activ level bothersom gradual declin igisi
score lower incid gi vs
year ms franchis provid top-lin stabil grow reliabl flat
low-singl digit compound-annual-growth-rate despit gener oral entranc howev concomit
threat multipl new entranc narrow window novartiss mayzent merck
kgaa mavenclad celgen ozanimod yet-resolv patent litig tecfidera
lack innov ms pipelin beyond vumer put shaki ground
ultim given establish ms commerci infrastructur increasingli
greater visibl g-tecfidera entranc barclay think ms portfolio
remain stabl revenu driver support expect rapid convers
vumer convers street expect impli measur vumer convers ramp
lead net eros fumar franchis one would disagre
particularli given attract safeti profil therebi keep patient on-therapi
lower price wac
expect competitor complic market anticip much biogen
focu maintain fumar share priorit convers patient
vumer tecfidera model flat perform eros
begin earnest entranc g-tecfidera captur tecfidera
share larg recov back pre-futil announc almost
one-year ago march reflect mix aducanumab street remain
mix approv tecfidera follow posit ipr decis
price target base npv sum-of-the-part analysi driven
contribut ms franchis spinraza biosimilar
aducanumab platform/piplin valu ex-aducanumab valuat
also reflect net cash well stake samsung jv ioni
tax assign long-term tax rate given expect product mix
 ou
discount rate model wacc standard assumpt larg
cap biopharma compani higher-beta/higher-risk stock rang
share count valuat appli dilut share outstand
risk price
regulatori risk downsid valuat weight regulatori risk biogen
fail obtain fda approv aducanumab and/or receiv unfavor regulatori feedback
us/ou risk includ oner studi requir chang drug
commerci risk eventu launch aducanumab could complic
heighten payor/govern scrutini could increas barrier access impact
uptake/sal sma payor preferenti includ spinraza formulari despit
ongoing/expect competitor launch outer-year declin could moder
ms stabl franchis increas competit could meaning drive sale
lower share declin
clinic risk engag inher high-risk neurosci research
mani mechanisms/approach yet valid leav guarante on-going
studi success given concentr increas studi failur
could weigh diversif effort
capit risk increas regulatori requir clinic burden slower-than-expect
commerci ramp could requir increas spend impact abil freeli
deploy access capit
bristol-my squibb compani quarterli annual ep usd
consensu number bloomberg receiv gmt
initi coverag bristol-my squibb equal weight price target
view bristol stronger better posit compani follow celgen acquisit
improv near-term growth profil broad new product cycl capabl
weather forthcom revlimid eliqui loss exclus howev
equal weight thesi reflect stock increas past six month vs nbi
skeptic data/approv move needl meaning
lung cancer like pace ozanimod launch multipl sclerosi near-term approv
ozanimod reblozyl posit ozanimod data ulcer coliti uc import
outlook also price separ hope posit data drive
rebound opdivo market share renal cell carcinoma rcc may overshadow
merck keytruda lenima like dampen impact
opdivo dynam lack confid recent clinic win translat commerci
sentiment bristol share improv backdrop import opdivo clinic win
even face growth go neg given headwind lung kidney cancer
didnt hear much compani call suggest ww opdivo growth
though model return growth dont see much risk nsclc
approv base may view larg peripher main act
data like april acknowledg there potenti upsid dataset
highli doubt match let alon best hazard ratio seen merck hr
bar wed surpris data drive opdivo share lung vs
pipelin event watch street understand focus cm-
updat view updat critic given
estim alreadi bake sale updat indic start
psoriat arthriti could see program peak potenti rise vs
peak today similarli high expect ozanimod data uc
data like immedi compar gilead filgotinib data expect
time-frame
valuat price target base blend dcf price-to-earnings
multipl appli project ep impli
initi coverag bristol equal weight price target
invest thesi reflect cautious balanc risk/reward stock
strong perform end understand recent ralli share given
posit opdivo data neg shift sentiment merck benefit bristol improv
visibl celgen deal close strong line-up launch particularli
backdrop attract valuat share ep start
ralli go forward howev think take meaning addit narr
and/or steadi string win drive multipl expans well ep given
patent cliff name histor trade within next year ep acknowledg
cliff may slope skeptic opdivo
driver given high hurdl merck set lung cancer evolv
benchmark fierc competit rcc dont get us wrong think help
margin adjuv set provid plenti new ground bristol
compet near term think bull need realist term potenti
move market share strong launch ozanimod cautiou ms coupl
posit data ulcer coliti uc strong show across phase psoriat
arthriti psoriasi might wow factor could impact
longer leg data take time emerg year
price target base blend dcf price-to-earnings multipl valuat base
ep estim dcf assum wacc termin growth
lead valuat appli price-to-earnings multipl assum project
ep estim impli roughli multipl street
averag biopharma group view appropri given
impend revlimid genericizaiton begin acceler
dcf sensit driver
timingev catalystbarclay expectationsmarch aprilapril data nsclc opdivo yervoy chemo top-lin data trial opdivo cabometinib rccexpect approv focus ozanimod label address first dose monitor anticip focu early-to-mid-stag pipelin asset well lcm effort near-term launch dayozanimod approv ms reblozyl approv mdsmain focu safeti efficaci express durabl respons compar keytruda dataset data compar believ show meaning differenti vs drive materi chang share opdivo keytrudabas strength phase data expect data posit look see data compar etrasimod top-lin phase data program psoriat arthritisfda approv liso-celtop-lin phase north data ozanimod uctop-lin phase poetyk data program psoriasistop dataset compani wide expect posit focu whether safeti hold end posit otezla biolog posit bias data provid de-risk second indic likley drive higher estim straightforward approv de-risk cvr focus languag around requir monitor in-pati requir barclay biopharmaceut
drive share near term
expect investor focu near term divid improv profil
near-term opdivo perform read-out view share benefit
past six month front improv awar leverag coupl
opdivo catalyst guidanc essenti spell acceler ep growth
think focu turn back opdivo model sale y/i though
expect uptick dont anticip approv back
move needl lung
street consensu forecast ep respect
neutral thesi reflect improv compel oper leverag near term
uncertainti like inconsist model ahead
celgen deal close fall ep consensu move
past six month may ultim addit upsid on-going
launch modest cost control addit share buyback think stock
near-term earn power larg understood even guidanc
argu conserv model revenu grow
y/i compar consensu
forecast ep grow compar
consensu respect
project adj ep op margin
opdivo perform remain focu
despit grow world-wide opdivo sale underli region dynam
underscor growth essenti stall temporarili mask strong ou
perform driven two underli dynam shrink nsclc
address popul given greater use i/o agent name keytruda
competit dynam kidney cancer reflect strengthen keytruda
opdivo continu effort lung cancer revolv primarili around two studi
part data present esmo subsequ file fda
set pdufa date later may expect data provid bristol
long sought-aft nsclc label express doubt meaning
impact market base talk kol argument made favor
chemo-spar option vs keytruda plu chemo practic clinician seem
recept cite combin numer inferior data figur keytruda
entrench posit base sole expect see meaning
inflect current off-label use nsclc low-singl digit figur
comparison pfs/o hazard ratio across subgroup
note hazard ratio updat
may pdufa date opdivo howev main focu present
result evalu opdivo plu yervoy plu two cycl
chemotherapi top-lin data octob disclos studi met primari
endpoint overal surviv littl els disclos importantli data
benchmark non-squam squamou keytruda
seen figur
particular look clariti
subgroup efficaci analysi across express squamous/non-
safeti combin
high-level view given subgroup analysi cut wed surpris
least one corner result opdivo combin look promis
rel keytruda said think hurdl high opdivo chang practic
behavior like translat meaning separ rel hazard ratio weve seen
keytruda hr os across
part armkeytruda chemoopdivo yervoypf hr hr hr hr hr hr hr hr hr hr barclay biopharmaceut
also worth note astrazeneca like present data poseidon imfinzi
plu chemo hit disclos top-lin releas back fall
data releas also like play role data interpret
investor split market back-end across chemo-combo set today
market share across brand nsclc
relev benchmark
merck present hellmann et al new england journal medicin
beyond lung data also await data kidney
cancer posit bristol manag key driver sale growth
adopt i/o agent front-lin set ramp quickli
driven adopt keytruda plu inylta follow approv fda
april basi approv set new benchmark rcc across
favor risk segment reduct risk death hr
month os rate vs sunitinib forthcom opdivo plu
cabometyx vs sutent compar expect posit result
primari endpoint though call clinician suggest need see
strike os benefit move needl commerci drive growth beyond
intermediate/high-risk patient opdivo use today inde rightli wrongli
suspect market dismiss threat keytruda segment studi
hit os first interim
particular focus combin efficaci profil across differ
risk categori adopt keytruda plu inlyta driven primarili
favorable-risk segment os result compel
higher-risk cohort well
benchmark os figur month
paz-ar et al new england journal medicin
concurr dialogu data also expect
evalu keytruda plu lenvima vs lenvima plu everolimu
downplay data due perceiv toxic combin uptak
phase data look compel toler profil may look better
set near term data add nois around opdivo potenti
rcc like facilit splinter market clinician look person
therapi patient co-morbid abil toler therapi
market share across brand rcc
point mind modestli street opdivo sale
vs modestli estim given
view around modest impact lung cancer see opdivo narrow gap
consensu closer potenti adjuv indic may come on-lin
seven launch contribut
mayb consensu contribut one attract
part bristol narr on-going potenti near-term launch across inreb
ozanimod reblozyl program howev
seven street number potenti upsid come commerci execut
half project revenu across program highli
competit area ms uc mm nhl bullish reblozyl
program would argu ozanimod consensu estim dont fulli reflect
competit intens ms challeng ramp ulcer coliti
challeng see sustain upsid estim final
bullish program clinic commerci program
de-risk phase psoriasi read-out later year although that
balanc potenti de-risk data psoriat arthriti could add anoth driver
across seven aforement ongoing/potenti launch street
estim forecast contribut grow
largest contribut ozanimod reblozyl
new product cycl come expect
seven launch outlin forecast contribut sizeabl
contribut given two product launch alreadi three
product program unlik launch
dont think estim unreason think like ozanimod
slow gate uc fail ramp fast predict cellular therapi
under-perform bristol meet estim figur
backdrop cover ozanimod reblozyl
program detail
consensu expect expect approv seven launch figur mn
ozanimod cautiou launch given ms competit dynam
ozanimod expect approv multipl sclerosi ms next month pdufa march
drug ultim label focu specif languag safeti
potenti monitor expect label address first-dos monitor
manner similar mayzent label recommend first-dos monitor patient
prior cv events/issu rather patient like gilenya broadli bit
conserv street given
drug current indicationsadd indic rs md ntd b-thal ozanimod-m uc mm total barclay barclay biopharmaceut
intensifi fight share mind novarti step market sinc
launch vumer mayzent respect dont see trend
revers given import brand respect franchis that
challeng backdrop bristol make debut ms field
potenti risk gilenya gener enter market
colleagu emmanuel papadaki note januari oral appeal hear
inter part review ipr gilenya go well novarti like leav
novarti minim protect orang book patent provid exclus
cover pediatr popul potenti gilenya gener enter
market month launch could add anoth layer complex
street consensu
dynam howev may overshadow forthcom phase ulcer
coliti uc data ozanimod north studi expect read
midyear ultim see ozanimod potenti inflammatori bowel diseas ibd
outperform ms launch import de-risk event even
think street bake success alreadi howev data expect midyear
presum file dont expect uc data ad label
addit gilead like read phase data filgotinib uc
program time potenti set drug launch concurr
gilead clear regulatori strategi timelin look beyond
potenti contribut close monitor competit
efficaci profil rel etrasimod pivot phase
uc data demonstr compel efficaci phase trial
anticip non-hodgkin lymphoma dlbcl approv august
bla recent accept drug given prioriti review
somewhat cautiou eventu launch given pace launch yescarta kymriah
persist question access reimburs note need
take share drug think there compel argument help
grow market take time given factor consensu
figur greater visibl launch evid
grow market
expect bristol file multipl myeloma approv set
approv late earli despit increasingli mix commentari around
long-term competit program heard lot anecdot evid
suggest latent demand product least among cohort patient
think bristol could treat patient grow
model price acknowledg remain larg unknown forecast
look beyond first coupl year launch howev competit intens
like pick notic highlight jnj/legend compel data
emerg anti-bcma therapi mind consensu
near term notabl start figur
reblozyl md approv wide expect remain bullish launch
reblozyl launch late approv -thalassemia april
pdufa date second indic ring-sideroblast rs myelodysplast syndrom
md patient requir blood transfus main driver behind
drug commerci potenti said approv wide expect like
straightforward sourc upsid reblozyl come
launch street reblozyl launch near long term
driven underappreci epidemiolog durat physician incent think
take late print street begin
move estim drug higher
clinic side data beyond studi non-transfus depend
beta-thalassemia patient posit wide expect
relev ou opportun take time access/reimburs come
on-lin beyond updat durat therapi seen phase medalist
md believ beta-th studi provid read-through drug
commerci durat use evolv time final updat life cycl
management/label expans strategi may also provid visibl indic
current reflect street estim overal bullish reblozyl potenti
think better way gain exposur near term share
estim shown figur
bristol oral inhibitor introduc investor septemb
present eadv concurr public nejm link inhibitor
drug believ mediat function signal axi valid
relev mechan psoriasi evid clinic success adopt il-
antibodi cosentyx taltz antibodi skyrizi tremfya
initi reaction focus drug differenti profil oral therapi score
efficaci approach biolog twice achiev otezla data
inde profil hold potenti transform psoriasi space take share
otezla biolog drug safeti look rel clean
hematolog safeti signal
back data known relev axi bristol launch
broad develop program across psoriasi also psoriat arthriti lupu
crohn ulcer coliti balanc expect phase data psoriat
arthriti well importantli pivot phase dataset psoriasi phase
studi conduct placebo otezla easili beat
said key focu investor next year
evolv safeti profil phase data less concern
import question posit perspect safeti profil
evolv patient data phase enrol patient mani
lower dose drug safeti profil hold avoid class label
black box warn hit jak date would major benefit
posit could ultim view signific efficaci oral option
otezla recal otezla pace gener sale across psoriasi
psoriat arthriti year
magnitud efficaci think there less sensit commerci around
efficaci profil closer drug come match efficaci level associ
inject biolog better add context efficaci profil
phase roughli compar efficaci level seen lower-dos
cosentyx drug gener novarti
emerg competit topic program well oral
program de-risk data year
given competit dynam despit lack de-risk data competitor
assign unadjust peak sale probabl success base
psoriasi alon said depend safeti profil evolv level
competit intens drug efficaci profil indic see upsid
scenario could drug time
week stelara vs enrol dec week vs pbo vs activ enrol juli vs pbo vs activ enrol dose vs vs barclay biopharmaceut
price target base blend dcf price-to-earnings multipl valuat base
ep estim dcf assum wacc termin growth
lead valuat appli price-to-earnings multipl assum ep
estim impli roughli multipl street averag
biopharma group view appropri given impend gener
threat revlimid begin acceler
dcf reflect project sale forecast take account project
market develop assum wacc in-lin bloomberg-report
wacc today also assum termin growth rate line standard
assumpt larg biopharma declin revenu termin valu year
also assum long-term tax rate take account share
repurchas plan payment conting valu right cvr
issu holder celgen stock probabl pay
risk rate price
upsid risk rate price target includ posit differenti data cm-
drive greater acceler opdivo sale current anticip
better expect launch and/or ozanimod better expect
oper leverag across
downsid risk includ slowdown opdivo sale disappoint ozanimod
data uc and/or data psoriasi failur integr celgen
 co quarterli annual ep usd
consensu number bloomberg receiv gmt
initi coverag overweight pt posit stanc
share driven convict around growth outlook durabl diabet
busi improv option around oncolog franchis improv oper
margin narr persist see dynam coupl
low loe risk support differenti growth profil rel peer next five-
year cagr rev vs peer ep vs justifi higher
trulic tirzepatid diabet driver today tomorrow despit price
competit concern diabet busi demonstr solid growth post
y/i good visibl around price headwind potenti polici chang
price less like least near-term class growth offset share headwind
trulic expect continu impress growth across trulic compound-annual-growth-rate
broader diabet segment initi phase data tirzepatid dual
inhibitor also de-risk franchis long-term given potenti disrupt
efficaci profil compel control weight loss would provid lilli
potenti bridg trulic near loss exclus loe toler
discontinu rate tirzepatid could neg impact strategi though
think refin titrat help
view next month critic period oncolog franchis approv
launch selpercatinib ret-posit tumor updat
cll like close watch verzenio data adjuv breast cancer
kra updat far either nearer-term see
immunolog franchis accret valu continu perform taltz despit
increas competit across psoriasi increas appreci increment
impact mirikizumab lebrikizumab help oper margin
valuat risk price target base blend dcf analysi
wacc npv sum-of-the-part npv sotp analysi
reflect contribut lilli key commerci franchis endocrinolog
oncolog immunolog neurosci probabl adjust
pipelin estim across key program selparactinib tirzepatid
alzheim effort total net cash risk valuat includ
clinic trial setback key pipelin program chang regulatori polici
insulin payor access increas commerci competit
initi coverag overweight pt
high rel valuat peer invest thesi lilli center
compani maintain differenti growth profil driven
out-performance across diabet busi stand today de-risk mid-to-
longer term diabet outlook posit phase tirzepatid readout de-risk
around next wave oncolog growth selparcatinib verezenio
continu leverag taltz build-out immunolog franchis see
dynam support improv oper leverag narr margin expans
expect mid-to-high
diabet commerci dynam look support tirzepatid sight
concern price intensifi run-up approv novo nordisk rybelsu
miss trulic howev concern wane start
rybelsu price par trulic figur rebound trulic
jardianc help off-set price share eros prove nearli
dramat mani predict look see gener stabl environ
good visibl around magnitud price headwind modest share eros
script trend support anoth year robust growth class think
dynam support solid outlook trulic jardianc separ
see start phase readout tirzepatid one impact clinic event
given import phase program extend lilli franchis
potenti impact diabet treatment paradigm
oncolog immunolog pipelin add new driver
next month provid signific visibl potenti oncolog
franchis like straightforward selparcatinib approv potenti high-
impact updat kra inhibitor updat verzenio
phase data adjuv breast cancer face competitor
challeng wouldnt character high-risk immunolog side
taltz continu impress commerci dont see olumi mirikizumab
lebrikizumab best-in-class see asset contribut
valuat driven blend dcf analysi npv sum-of-
the-part analys price target impli multipl
ep sector multipl justifi view magnitud
differenti growth profil increasingli compel pipelin
timingev catalystbarclay tirzepatid data posit data strength phase focal point magnitud weight loss discontinu rate new titrat scheme full-dat expect next year anticip built-in interim could reach back half could impact ibranc timelin slip interim read-out monarch-estraightforward approv focus decid price drug selparcatenib approv retfus nsclc ret-mut mtc retfusion-posit thyroid cancerphas data ulcer coliti mirikizumabexpect induct data phase data show clinic remiss rate endoscop heal dose phase data psoriasi mirikizumabdata posit given prior phase data placebo-adj score howev low-expect come close match skyrizi efficaci focu durabl respons respons rate greater follow-up patient updat phase bruin studi cll barclay biopharmaceut
endocrinolog franchis reach
ye think driven growth trulic tirzepatid jardianc model
endocrinolog busi grow impli compound-annual-growth-rate notabl
street number modestli four risk
forecast slow growth meaning eros trulic rybelsu
clinic risk tirzepatid price risk hear near-zero worri first see
evid second view tirzepatid meaning de-risk alreadi see new
increment price risk emerg least next mayb month
what price
street model endocrinolog franchis show growth compound-annual-growth-rate
endocrinolog remain engin lilli growth
lilli endocrinolog franchis close high note shrug concern
price competit post sale y/i franchis driven
primarili lilli diabet asset critic lilli therapeut area account
compani overal revenu franchis well-diversifi across
 trulic jardianc dpp-iv tradjenta insulin
benefit secular dynam space rise use
option metformin
backdrop near-term trulic inhibitor jardianc
commerci relev product growth perspect gener
y/i y/i respect expect product
coupl expect de-risk approv launch tirzepatid dual
drive franchis offset eros product figur figur
consist street estim
driver growth bn
visibl price headwind risk
concern price compress across diabet franchis persist concern
share driven emerg competit potenti reform
drug price polici competit approv novo nordisk rybelsu late
septemb focu though disclosur drug would price par
trulic effect allevi concern despit dynam lilli offer soft
guidanc trulic see pressur net price harmon
contract payer consolid
polici front howev number propos put forward
side aisl includ white hous intern price prescript
drug price reduct act grassley-wyden medicar hous
democrat price propos pelosi despit flurri activ limit
evid suggest closer enact today last summer
particularli advanc elect implement global refer
price could neg effect lilli diabet franchis see impact
mute given implement would come five year lilli net price far
list price give option lower list price minim differenti
overal see minim tangibl risk lilli beyond headlin risk run-up
elect though anticip revisit elect
trulic unaffect rybelsu thu far
trulic lead market share base run-up
launch oral rybelsu concern trulic would see rapid share
eros initi prescript trend howev survey work complet eu pharma
colleagu emmanuel papadaki suggest modest eros european pharmaceut
show trajectori trulic new prescript total prescript look
unchang figur figur victoza notabl impact european
pharma team survey endocrinologist primari care physician also
ask expect market share would move today two-year
note
class expect see share growth next
two year expens insulin dpp-iv figur
trulic see modest eros share loss
predominantli come once-daili victoza figur
us market new prescript nrx week
us market total prescript week
project chang class share month
project chang share month
base data point project trulic sale figur
project headwind price off-set demand growth y/i
period estim
respect street estim period thought anoth
way model impli price pressur would increas addit
annual bring estim line consensu
project trulic sale driver
tirzepatid subcutan inject dual receptor agonist critic
futur lilli diabet franchis dual target major incretin believ
offer better glycem weight control vs tradit phase data figur
figur present easd annual meet demonstr dose-depend
improv control well weight loss period vs trulic
addit data tirzepatid evalu differ titrat dose scheme
biopharma market model mn except trulic us chang barclay biopharmaceut
demonstr still compel result shorter period week vs week put
context tirzepatid drastic outperform lead almost clinician
takeaway highli support view result potenti transform
impact tirzepatid level first phase
impact tirzepatid weight loss first phase
impact tirzepatid weight loss titrat dose
impact tirzepatid weight loss titrat dose
scheme week
enthusiasm tirzepatid efficaci off-set somewhat concern toler
rate discontinu seen initi phase data dose titrat
studi show mix benefit toler treatment-rel discontinu
fall notic phase titrat studi impact
nausea/vomiting/diarrhea mix
safeti toler tirzepatid
back data lilli launch broad phase diabet clinic program
surpass data begin read-out later year like
perhap figur monotherapi studi treatment-nav
import earli studi read-out also view given
ozemp posit marketplac elev cv risk key studi
defin drug use long-term cvot recent start
critic though data expect separ lilli also develop
drug nash synergi obes surmount
tirzepatid phase program
potenti file tirzepatid look potenti switch dynam
tirzepatid aforement survey survey physician indic
would switch patient tirzepatid phase data
recapitul on-going phase program importantli howev
switch indic come trulic suggest room tirzepatid grow
lilli overal share cannib trulic import think help lilli
case versu posit trulicity-to-tirzepatid switch narr around
time trulic loe drive sale project
patient switch tirzepatid
switch tirzepatid
project trulic tirzepatid ww sale
respond patient switch year barclay biopharmaceut
updat across immunolog oncolog
franchis drive increment valu year
ye see immunolog set rel easi straightforward clinic win
mirikizumab readout albeit set compani heavi lift
commerci side peak sale opportun unlik narr shift
see leverag exist infrastructur effici help de-risk oper
margin expans narr oncolog updat probabl hold investor attent
selparcatinib approv straightforward launch close watch
expect updat verzenio adjuv data grow compon
narr
street forecast immunolog grow oncolog side
asset like contribut meaning franchis sale growth
think underestim term import narr
launch taltz provid compani foundat piec immunolog
franchis one point olumi suppos add anoth potent driver
blockbust potenti limit safeti question around dose
limit label go forward see lilli complement taltz low-
clinic risk asset mirikizumab lebrikizumab compani leverag
exist infrastructur would argu neither program get much excit
street given limit differenti think lilli still abl leverag
commerci presenc drive sale across product provid
solid sourc oper leverag
continu growth taltz taltz benefit rise next-gener novel
biolog across psoriasi biolog beyond anti-tnf trend believ still
leg decad given competit natur market dont see
clear event drive inflect pace growth rather expect
blocking-and-tackl solid commerci execut drive product sale gradual higher
model sale grow compound-annual-growth-rate
lebrikizumab think lebrikizumab find challeng carv nich
context dupix five-year-plu headstart potenti novel agent
launch interim tezepelumab jak acknowledg atop
dermat market larg enough even minor share could drive meaning
revenu particularli lilli leverag exist infrastructur lebrikizumab
longer dose interv vs dupix vs expect lilli leverag
well find addit life cycl manag opportun model risk-adjust sale
like posit data mirkizumab phase mirkiziumab data expect psoriasi
ulcer coliti low expect term differenti
rel note provid compani
jak inhibitor essenti give foothold major growth class
model sale reach
driven factor model franchis sale grow five-year
lilli oncolog franchis gener sale alimta account
almost half despit legal win close street
still model loe impact begin importantli compani acquisit
loxo oncolog provid lilli new product cycl wave compris
selparcatinib
investor attent around loxo acquisit primarili focus around
selpercatenib loxo btk inhibitor drew investor attent compel
data coupl merck acquisit arqul compet program btk
program abbvie/jnj imbruvica domin forc chronic
lymphocyt leukemia cll acquir resist commonli mutat limit
effect percentag patient revers inhibitor target
popul small phase trial bruin updat demonstr
respons rate cll patient includ patient without
mutat merck/arqul program longer follow-up demonstr somewhat
similar respons rate patient qd dose think remain
earli meaning compar program expect updat
look updat lilli next step includ potenti regulatori
strategi extent may abl devis strategi address patient
segment beyond mutant popul post imbruvica therapi
note loxo acquisit primarili driven lilli interest selpercatenib
oral inhibitor ret kinas alter common driver sub-seg solid
tumor includ lung cancer thyroid cancer other drug nda recent
submit fda grant prioriti review agenc set
drug approv estim would posit selpercatenib launch
approxim least quarter ahead approv blueprint pralsetinib roll nda
expect complet look across program think selpercatninb
moder better respons rate data nsclc predominantli treatment-nav patient
think drug use appear moder better toler
profil support lower discontinu rate dataset continu
monitor evolv confirmatori phase program player
valuat driven blend dcf analysi npv sum-of-the-part
look lilli franchise/therapeut area basi given import diabet
potenti growth narr across immunolog oncolog
dcf model sale relev commerci product key
late-stag product earlier-stag pipelin estim cash flow sale
base oper margin tax-rat assumpt project incom
statement thereaft long-term assumpt margin low-
tax-rat deriv present valu termin valu lt growth rate
cash flow assum weight averag cost capit line
npv franchise/therapeut area assumpt use
project sale estim sum within respect franchis
assum oper margin franchis level rang subtract
tax arriv project cash discount valu present day use
wacc calcul termin valu long-term growth rate assumpt vari
flat across franchis base assumpt assign valuat
individu franchis level figur
summari npv analysi
risk price target
risk price target includ neg clinic data tirzepatid slower class
growth class renew drug price concern
commerci risk selpercatenib
inc quarterli annual ep usd
consensu number bloomberg receiv gmt
initi coverag gilead scienc underweight pt thesi center
increasingli challeng risk/reward share re-rat higher
remdesivir potenti applic coronaviru stock tack
increment enterpris valu feb close acknowledg remdesivir
may prove efficaci though larg anecdot
address major health crisi doesnt necessarili translat gilead
abil commerci monet drug commensur stock move inde
uncertainti swirl remdesivir ip china potenti price sustain
revenu gener current stock hand manufactur capabl drug
import nation secur see stock trade headlin rather like
lack visibl next growth driver anticip pace filgotinib launch think
approv filgotinib rheumatoid arthriti ra pdufa aug straightforward
see low probabl fda deviat class label there case made
best-in-class posit far overwhelm skeptic
stand face competit backdrop
street number see low probabl narrative-chang launch
puzzl filgotinib consensu look almost higher rinvoq
actual vs similar stub launch period aug-dec
hiv franchis growth fine post-descovi time-frame increasingli
focu forecast continu convers biktarvi compound-annual-growth-rate descovi
growth peak underpin hiv franchis
near-term said descovi loss exclus loe expect point
biktarvi growth wont suffici off-set bigger pictur hiv franchis
durabl gener signific cash flow near-to-mid-term see less
room upsid outer-year hiv revenu ex-biktarvi still requir de-risk
capsid inhibitor
valuat risk assign price target base npv sum-of-the-part
analysi contribut hiv portfolio hcv filgotinib
yescarta/car-t net cash plu galapago stake
risk thesi includ approv and/or meaning windfal payment relat
remdesivir coronaviru acceler prep util us differenti label
filgotinib ra and/or escal busi develop activ
initi coverag gilead underweight pt
gilead antivir busi domin narr past decad transform
hiv cure hepat howev declin hepat hcv busi
larg round error taf/tdf convers hiv late inning
pertin question face gilead growth come compani
done admir job grow number gener headwind recent year
driven hiv franchis y/i see franchis growth grind
halt compani attempt address growth profil
opportunist acquir right filgotinib move car-t kite
acquisit talk next wave innov hiv long-act inject
broaden partnership galapago earli day mani effort
fact move minim impact top-lin date inde
suspect investor pin hope fast filgotinib launch specul
potenti remdesivir coronaviru disappoint would recommend higher
qualiti growth narr space lilli merck regeneron
biktarvi descovi provid growth hiv franchis look flat
hiv franchis dictat three factor continu biktarvi growth
street descovi adopt prep larg in-lin hope around next wave
innov asset outsid model given timelin de-risk
data worri commerci perform franchis near-
term difficulti see path growth thereaft biktarvi growth
moder share hiv market move rang
suspect new innov option wouldnt launch
filgotinib fourth oral jak inhibitor launch pdufa august gilead first
rheumatolog launch pit compani lilli think
there case made best-in-class posit straightforward think
overwhelm entrench competit street number
pt base npv sum-of-the-part analysi assign valuat
hiv portfolio hcv filgotinib yescarta/car-t net
cash plu galapago stake model discount rate risk includ
entri transform busi develop ad meaning growth driver
npv waterfal gilead
timingev catalystbarclay expectationsapril pdufasept remdesivir trial trial chinaw expect data demonstr activ think updat need come commentari surround commerci monet see stock continu worktop-lin data phase select studi filgotinib ucstudi wide expect posit data like comp rinvoq xeljanz clinic endoscop remiss rate week rinvoq rate histolog remiss week top-lin data phase north studi ozanimod ucsom eros brand truvada gener look percentag market alreadi convert descovi aggress payor manag prep space given histor limit lack optionsfocu clear dose-respons identif sub-group may reduc risk potenti phase studydata phase roccella studi osteoarthritisw expect filgotinib receiv class label inclus black box warn infect thrombosi recommend lab monitoringlaunch teva truvada genericefficaci jak compar first phase data modul uc think jak efficaci data look better ozanimod close may take share due better safeti profil though necessarili ozanimod barclay biopharmaceut
remdesivir coronaviru drive valu gilead
skeptic remdesivir drive increment valu gilead let clear gilead
move suppli drug right move broader respons societi well
drug develop perspect said magnitud stock move reflect
exuber around fast move news topic hedg volatil marker rather
consider data anecdot data consider regulatori
acknowledg urgenc uniqu situat challeng conceiv
windfal payment would move needl gilead sake refer
note govern spent order build stockpil two ebola
vaccin two therapi
sinc new england journal medicin nejm public remdesivir januari
gilead share versu nbi ad compani enterpris
valu februari
background remdesivir coronaviru
remdesivir novel antivir therapi nucleosid analogu incorpor nascent
viral rna chain result prematur termin though drug initi pursu
ebola exist anim model data suggest efficaci emerg coronavirus
cov date back base data well anecdot evid efficaci
remdesivir one coronaviru patient publish nejm
subsequ vitro studi relat coronaviru suggest efficaci remdesivir
chines research launch two studi mild-moder sever evalu
remdesivir patient chines offici expect
provid result studi april illustr success launch
windfal payment gilead would equat valuat
publisheddateevidencejan articl washington state case resolut symptom administr remdesivirfeb research articl vitro data coronaviru suggest remdesivir chloroquin efficaciousfeb media announc initi remdesivir trial patient studi w/ mild moder infect patient studi w/ sever infect barclay biopharmaceut
hiv franchis growth profil
forecast growth flattish revenu descovi gener
kick word see hiv franchis provid ballast revenu line
valuat unlik provid sourc growth multipl expans name
anticip increas constern around next wave growth hiv
franchis move biktarvi growth moder strong
launch truvada gener erod brand prep market
street forecast modest growth number follow modestli
higher growth expect explicitli number
expect hiv abl deliv anoth wave innov space
gilead hiv franchis help sustain revenu line face hcv declin
actual drove top-lin growth franchis grew y/i look
forward see coupl move part dictat franchis perform
biktarvi entrench standard care hiv
eros cannib older product biktarvi
growth prep opportun switch descovi truvada
forecast hiv sale
franchis sale sinc biktarvi launch feb
gilead launch biktarvi earli provid strongest offer yet
combin tenofovir alafenamid taf next-gener integras inhibitor
combin offer differenti efficaci eas
administr small pill size daili dose improv safeti bone safeti less risk
renal toxic help drive rapid uptak evidenc report sale figur
critic allow biktarvi grow gilead overal share gain
compet dolutegravir regimen cannib gilead product
shorter patent live essenti extend franchis project gilead exclus
period extend us europ gilead comment
major gain come cannib prior
product older tdf product genvoya rest come
math believ biktarvi overal market share rang base
kol feedback suspect still room almost doubl
forecast persist share eros across older taf product genvoya odefsey
period cagr respect odefsey pre-expiri
backdrop growth linger concern new approv
name viiv dolutegravir-bas regimen dovato juluca despit rel limit
adopt two investor focus juluca rilpivirine/dolutegravir given
posit nrti-spar regimen could counter gilead tdf-base
regimen howev given move away tdf taf reduc risk renal
injuri see posit less compel
biktarvi perform quarter mn
fda approv expans truvada prep hiv segment gilead
previous dismiss commerci opportun subsequ year truvada use
segment rapidli expand lead patient use prep essenti
share target patient appropri therapi figur conjunct
broader convers tdf taf gilead pursu develop descovi
taf compar truvada prep set lead approv late
alreadi seen inflect descovi use sinc addit prep indic
recal descovi also use hiv treatment though use declin figur
howev estim much growth date driven
cannib truvada gilead focus convert patient goal
prep patient descovi achiev conserv view
estim us
altogeth model much gener impact weigh brand truvada
onset limit impact descovi though ultim expect gilead
manag competit expiri estim descovi prep sale
total ww consensu year peak prep sale ww
consensu backdrop slow prep util curv
look annual pace y/i near-term reach last year
nonetheless remain upsid opportun beyond cannib though
like long-term strategy/dynam addit entrant emerg specif prep
remain underutil elig still therapi especi us south
cdc note high hiv diagnosi rate
 patientsprep trxdescovytruvadadescovi prep prep barclay total descovi sale barclay consensu barclay biopharmaceut
filgotinib launch street expect
dont think least initi year think there potenti case
make filgotinib best-in-class across jak differenti overwhelm
kol appear view larg undifferenti perhap importantli
commerci execut space trivial lesser
extent lilli meaning presenc jak space unlik cede share
quietli didnt expect filgotinib number meaning drive inflect
top-lin near-term see solid launch import sentiment separ
phase data ulcer coliti uc data expect also wide expect
posit data compar histor remiss rate jak
consensu estim forecast filgotinib sale grow
gilead filgotinib jak inhibitor wide expect fourth jak inhibitor approv
rheumatoid arthriti ra august pdufa date ra market still
larg domin biolog name anti-tnf promis efficaci oral agent
driven hope oral jak class given meaning head start pfizer xeljanz
tofacitinib current lead agent lilli olumi baracitinib low-mid
singl digit share figur rinvoq entranc howev upend
dynam grow high-singl digit share date larg expens xeljanz
given preced rinvoq label expect gilead filgotinib standard
class label jak black-box warn infect thrombot risk
recommend lab monitor though possibl differenti label could
rise get closer approv date
battl fought
despit long domin histori inflammation/immunolog market
establish commerci infrastructur humira note rinvoq launch
modest sale sinc august launch
ultim think jak hold potenti oral option ahead
biolog doubt initi use come set rather suspect initi
use initi biolog similar dynam saw otezla launch
psoriasis/psoriat arthriti expect newcom fight
rel small pie biologic-experi segment abl get payor
permit use earlier paradigm regard expect gilead newcom statu
disadvantag
acr respons week mtx-ir patient
acr respons week bdmard-ir patient
look respect phase dataset see roughli compar score
filgotinib vs rinvoq data pre-biolog set post-
biolog shown figur figur look data
specif point favor rinvoq other favor filgotinib whole
think data could support argument filgotinib wors rinvoq think
data mix enough clinician like view undifferenti
efficaci safeti filgotinib appear moder lower risk embol venou
thromboembolism/pulmonari embol vs think
born real world popul conclud differenti
part dont think expect overli optimist near-term
see downsid forecast includ launch filgotinib uc
forecast sale respect vs street consensu
trx jak across rheumatolog
share ralli last week sinc news remdesivir potenti
util coronaviru outbreak despit us patient ad
valuat backdrop increasingli uncertain commerci posit
prep inflamm filgotinib busi look
pt base npv sum-of-the-part analysi driven contribut
hiv hcv platform filgotinib yescarta/car-t
net cash plu galapago stake
tax assign long-term tax rate
discount rate model wacc base standard assumpt larg cap
biopharma compani fall in-lin report wacc bloomberg
share count valuat appli dilut share outstand
risk rate price
commerci risk given gilead commerci experi manag payor
formulari compani could exceed expect modest filgotinib launch
quickli gain share jak competitor rapidli convert
maintain prep share descovi ahead g-truvada later year clinician
patient payor posit posit descovi benefit truvada increasingli
favor car-t use would also present upsid expect remain minim
dynam would key upsid view
regulatori risk eas regulatori requir and/or favor drug regul
guidelin creat upsid risk valuat expect gilead immin launch
undifferenti class filgotinib jak class label cell therapi
car-t develop remain oner posit chang could speed time-to-
market lessen oper cost
clinic risk gilead engag number develop program target toward
common well novel mechan therapeut area unexpect success
nash could accret valu estim share
capit risk escal use capit execut transform bolt-on
busi develop could improv long-term outlook platform ad anoth
growth driver share
merck co inc quarterli annual ep usd
consensu number bloomberg receiv gmt
initi coverag merck overweight pt share notabl
underperform across pharma ytd vs drg driven variou keytruda worri
competitor data releas cours concentr risk recent concern
dilut distract impact women health spin-out spin
improv compani alreadi differenti growth profil pro-forma cagr
revenu ep estim reduc risk around top-lin profil
januvia/janumet loe keytruda concentr point
pushback eight year loe see misplac concern think nois
around competit dissip given low probabl keytruda get displac lung
kidney cancer may take play acknowledg
spin dynam may domin narr near-term expect earn
power new come focu timelin narrow close
angst competitor dataset overdon competitor updat across lung
potenti approv data poseidon kidney cancer
domin discuss particularli backdrop mute set
catalyst keytruda said dont see displac benchmark
non-squam nsclc non-smal cell lung cancer bar clear beat doubt
single-digit market share reapport similar dynam renal
get competit catalyst coupl visibl neo/adjuv
opportun triple-neg breast cancer tnbc would like enough revers
sentiment back merck favor
keytruda forecast modestli street keytruda
estim expect lung revenu grow
driven domin share grow i/o util use integr
adjuv set
valuat risk pt base dcf analysi wacc termin
growth current merck busi inclus women health legaci brand
biosimilar risk price target includ slow keytruda growth key indic
clinic trial setback adjuv indic delay failur spin-out women
biosimilar busi polit risk relat drug price
initi coverag merck overweight price target
merck revit past six year driven keytruda establish
backbon multipl solid tumor indic outpac rival across number
indic notabl lung cancer recent weak share net
impact multipl factor neg keytruda studi outer-year keytruda estim
climb significantli posit competitor dataset keytruda miss
word perfect storm sinc weve seen keytruda estim come
bloomberg consensu share declin drg improv
risk/reward view near-term competitor dataset highli unlik impact
keytruda share given strength key keytruda dataset particularli lung
expect dynam play
spin improv growth profil bring attent oper leverag
acknowledg benefit propos spin-off merck women health legaci
biosimilar busi somewhat distract give timelin close
dip margin howev think that short-term think given merck
emerg domin i/o franchis also fastest rise oper
margin look fair basi addit move also
see merck oper move in-lin peer
pt base dcf analysi wacc termin growth current
merck busi inclus women health legaci brand biosimilar risk
price target includ slow keytruda growth key indic clinic trial setback
adjuv indic delay failur spin-out women health biosimilar
busi polit risk relat drug price
timingev catalystbarclay tirzepatid data posit data strength phase focal point magnitud weight loss discontinu rate new titrat scheme full-dat expect next year anticip built-in interim could reach back half could impact ibranc timelin slip interim read-out monarch-estraightforward approv focus decid price drug selparcatenib approv retfus nsclc ret-mut mtc retfusion-posit thyroid cancerphas data ulcer coliti mirikizumabexpect induct data phase data show clinic remiss rate endoscop heal dose phase data psoriasi mirikizumabdata posit given prior phase data placebo-adj score howev low-expect come close match skyrizi efficaci focu durabl respons respons rate greater follow-up patient updat phase bruin studi cll barclay biopharmaceut
ye think forecast sale driven continu domin share
across lung kidney cancer despit nois around emerg competit threat ou
growth overlaid adjuv indic begin come around period
acknowledg grow trivial
make challeng find upsid would argu recent shift sentiment around
share much near-term outlook around near-term perform
around aforement competit headwind cloud outer year estim
street consensu keytruda sale estim clearli rocket higher
tail-end last year come
recent month least bloomberg dont view definit word
subject think clear say trajectori revers month
recent perform strong disrupt paus
despit keytruda sale grow y/i street focus
print sale grew sequenti flat ou compani attribut
eu price adjust part broader label good develop
inventori reduct japan ahead price cut earli year would also point
sale saw q/q growth inde global iqvia data monthli trend
confirm soft start japan appear drag ou volum
suspect pressur japan fulli abat analysi
keytruda vs opdivo share trend base global iqvia track suggest strong trend
still favor keytruda
keytruda sale reach opdivo sale
eclips grow y/i
recent quarterli perform keytruda vs opdivo
inde see three domin near-term driver
continu roll-out eu adopt lung back lung
major market mover look share trend across eu market provid
sens roll-out see continu share gain across germani
reimburs lung start similar though pronounc
dynam play franc importantli move come
backdrop strong growth util across class exampl volum
franc y/i combin class growth share
gain see continu play lung
growth rcc see similar dynam play rcc albeit
ou keytruda plu inlyta drive go share gain also broader
adopt i/o therapi kidney cancer believ earli inning
dynam outsid give merck insid track view
market peak
potenti near-term file neoadjuv tnbc merck report posit data
demonstr signific impact patholog complet
respons rate vs vs chemo alon reduct risk
progress still wait potenti file strategi emerg could
open anoth opportun merck clear head start
chang keytruda share vs opdivo germani
chang keytruda share vs opdivo franc
part shift sentiment around merck begin toward end
sheer number competitor dataset uncertainti impact keytruda
dynam lung posit data read-out bristol studi
well astra poseidon across studi main take-away
bar best high hr basi base
discuss clinician take clear beat order drive shift
paradigm given merck entrench domin statu see anyon match let
alon beat low probabl event
truda non-squam squamou lung cancer
across kidney cancer also await data bristol
posit bristol manag key driver sale growth
combin keytruda quickli gain share see tall hurdl
bristol combin match benchmark data insurmount
said clinician look clear signal differenti enough
subgroup wouldnt surpris bristol find nich outperform
think come total data see drive chang behavior
benchmark os figur month
wave keytruda dataset
think emerg dataset potenti competitor
keytruda-involv dataset number impact data read-out could
drive growth includ two studi could open use
adjuv tnbc earlier-lin use lung cancer like import
lever look keytruda share set releg off-label
use account low-singl digit share
base dynam forecast keytruda sale grow
modestli consensu note forecast impli compound-annual-growth-rate
sale period compound-annual-growth-rate ou sale time-frame
chemotherapyawait final first os lenvimamay counter ef stage iiikeytrudacould de-risk earlier line open broad adjuv barclay biopharmaceut
perhap shot goal howev would argu minim
downsid ahead catalyst given there minim valu impli pipelin
current share price nevertheless keytruda concentr risk regular bear
argument data counter messag would increment posit
share primarili focus gefapix former head
start vs next wave pneumococc vaccin unclear
translat commerci benefit gefapix chronic cough underappreci
market minim novel competit
much street consensu impli cumul contribut vericiguat
islatravir half come islatravir
howev stock ytd vs drg would argu near-zero
valu impli stock around program
non-oncolog event merck
drugeventtim considerationsvericiguatvictoria data present heart failur late march magnitud mace benefit percentag patient background entresto perform patient data pediatr adult pneumoccoc recapitul impress efficaci seen phase data endometriosisphas data chronic de-risk evid endometriosi model impact effect tast tolerabilityislatravirhiv prep safeti profil given high bar prep insight target hiv infect patient year descovi phase vs truvada barclay biopharmaceut
margin reset lower grow faster back half
set oper margin essenti caught potenti
sooner depend conserv merck regard effici
commun notabl expect leaner structur allow new
effici reduc keytruda royalti translat better higher oper margin
vs previous model
consensu estim previous model margin expans stall around
notabl benefit re-set keytruda royalti
spin bring attent lt margin improv
spin-off merck women health legaci brand biosimilar busi
design shine spotlight strength busi
reorgan oper structur see oper margin rise well level
previous consensu stall figur figur
evolut margin vs pre-spin consensu
merck reflect pro forma estim
appreci neg optic revenu oper margin ep
essenti re-set lower distort common compound-annual-growth-rate analys think
make sens look compani revenu margin ep profil
compar use base year sake simplic assum spin
complet start acknowledg expect close end
basi expect merck show differenti profil two respect
expect merck show largest improv oper margin gain
outpac even lilli
merck also rejoin pack margin ad anoth leg stori
understand import near-term financi import think
disconnect handwring lack upsid keytruda number also
neglect consid oper margin expans period
pt base dcf analysi current merck busi inclus
women health legaci brand biosimilar project sale forecast
account relev market develop wacc
conserv rel bloomberg report wacc larg in-rang last
month termin growth in-lin standard assumpt larg
biopharma declin revenu termin year
risk price target
risk price target includ slow growth keytruda key indic
includ nsclc rcc broadli disappoint data and/or undifferenti data
keytruda adjuv indic posit differenti competitor data rel
keytruda delay execut spin-out women health biosimilar
busi polit risk relat drug price reform
quarterli annual ep usd
consensu number bloomberg receiv gmt
initi coverag equal weight price target expect
emerg transform divest upjohn consum jv later year
better posit improv growth profil repriev
meaning near-term loss exclus howev share alreadi trade
premium peer price-to-earnings remainco pro forma ep vs month
deal like close like go take either string meaning clinic win
includ ibranc adjuv breast cancer estim market opportun
uptick strateg busi develop activ get investor comfort
small molecul loe cliff end timelin push
palla earli doesnt help adjuv ibranc critic must-win
patent cliff remain daunt small-molecul patent cliff
like remain overhang share see like win abrocitinib
ibranc adjuv alreadi bake street number
vari extent two biggest offset eros period ultim
face loe toward end decad ibranc vyndaqel
upcom analyst day march expect focu underappreci growth
across mid- late-stag pipelin gene therapi platform diff vaccin matern rsv
rest immunokinas dermatolog portfolio well potenti top-lin abrocitinib
near-term catalyst watch near-term abrocitinib phase data
competit dupix itch relief off-set toler concern
children expect respect high import
mix result also look continu vyndaqel growth ibranc
valuat deriv price target base assign price-to-earnings multipl
ep view appropri given nearer-term loe-
challeng compani trade peer group pricet would
impli price-to-earnings multipl roughli pro forma remainco ep estim
risk upsid includ narr shift busi develop posit data
diff mid-term guidanc current consensu downsid risk includ neg ibranc
data failur realiz cost save poor busi develop activ
initi coverag equal weight price target
pfizer strateg move divest consum jv upjohn merger leav
faster grow innov focus compani provid window
address massiv loe cliff start near-term growth profil differenti
rel peer histor profil compani upbeat pipelin
potenti compani need string togeth number high-profil win would
argu abrocitinib importantli ibranc adjuv breast cancer
make compel case street absenc uptick busi develop
activ ibranc palla data expect investor may
patient enough wait particularli there pipelin stumbl
compani doesnt shift messag around busi develop coupl deal
close mid-year compani downplay buyback near-term
see challeng setup multipl expans stock alreadi trade
premium peer
expect high late stage pipelin
stake lot transform late-stag pipelin read-out name
abrocitinib atop dermat pneumococc vaccin
ibranc adjuv breast abrocitinib compar studi head-to-head
standard care dupix provid clear view drug efficacy/toler
trade-off commerci potenti clean win could add quadrupl peak sale
estim consensu estim today expect
tolerability/discontinu question linger diff
potenti drive inflect growth across vaccin busi provid
durabl revenu contribut howev critic pipelin event ibranc
palla data posit bias studi po addit delay
rais question trial underli assumpt
deriv price target base price-to-earnings multipl ep
base consider total pfizer p/l profil name top-lin growth
ep growth profil touch peer clear loe-challeng peer set
trade price target would impli price-to-earnings multipl roughli
pro forma remainco ep estim
timingev catalystbarclay expectationsmarch expect penelop data posit investor read-through outcom palla import two trial data palla expect earli interim data could also come compet monarch- studi similar time-frame expect deal close time expect vyndaqel sale reach driven strong growth us ou penelope-b data verzenio monarch- data updat vyndaqel growth trajectorymylan upjohn deal closingupd across rcc space focu mid-to-l stage pipelin potenti topic data data could come investor day expect posit result focu efficaci data evolv phase drug toler profil top-lin phase abrocitinib data atop dermatitisinvestor dayinlyta benefit rapid uptak keytruda plu inlyta rcc could threat potenti paradigm shift datasetx expect model inlyta sale grow annual barclay biopharmaceut
new pfizer look like
forecast emerg spin-off upjohn separ
consum jv improv top-lin profil pro-forma cagr rel
prior compound-annual-growth-rate rev flat notabl see smaller sustain top-
line set pipelin larger impact play
next three year coupl like margin expans narr see
dynam put better stand rel peer though loe overhang like
limit upsid
consensu estim challeng untangl given variou report approach
totalco remainco mix said think fairli well appreci top-lin
growth rate elev mid-singl digit ep growth outpac
upjohn/mylan merger viatri expect close new set
final emerg year discuss strateg altern ceo chang
year logist variou reorgan high level view
revenu reset lower grow faster remainco top-lin exclus deriv
biopharma busi new see revenu rang
estim vs guidanc notabl smaller
report revenu see sustain base given recent drag
upjohn segment lesser extent consum jv busi forecast
remainco top-lin grow annual faster
biopharma/upjohn combin driven acceler growth across number
oper margin start lower expand quickli margin hover
around compani guid earn tax ebt
margin roughli back incom translat roughli
oper margin see fair yet conserv guidanc expect
oper margin quickli rise eclips
ep reset lower grow faster guid pro forma remainco ep
barclay total compani print
lower base howev expect compani grow ep compound-annual-growth-rate
well growth combin biopharma/upjohn busi note
model minor share buyback reduct share count per year note
compani emphas deploy capit busi develop
stake outgo busi shed jv busi retain
econom share net profit book incom line
retain on-going econom interest viatri though sharehold receiv
stock new ventur viatri make payment
separ consum jv merger gsk leav gsk control busi
retain econom interest recogn interest
incom line report one-month lag
note follow section bull case highli depend upon clinic
execut across exist pipelin addit tuck-in acquisit similar
array acquisit consumm summer compani guid
oper cash flow also like signific net debt
time close question outer year revenu see next section see
provid adequ ammunit addit deal-mak though think
make challeng imagin larger transform deal
forma remainco top-lin acceler
pfe revenu growth divis
pfizer remainco ep could grow
compani report barclay research estim
pipelin off-set
without ad addit asset face small molecul
revenu compani number high-profil clinic catalyst
launch could add meaning driver two larger contributor growth post-
ibranc vyndaqel also go gener time-frame
complic calculu compani potenti new launch help
unlik fill gap stock perspect see challeng setup given
asset abrocitinib vyndaqel ibranc adjuv data
alreadi street number inde ibranc adjuv data like hold upsid
potenti street estim alreadi price increment revenu peak
today number mind wed rather take wait-and-se approach
clariti compani busi develop effort array deal nice startbut
start
dont see much varianc magnitud challeng face
estim peg loe cliff rang propos revers engin increment
revenu opportun ibranc adjuv breast cancer estim street
alreadi price probabl success number abrocitinib
also model street vyndaqel peak sale estim
number expect five-year period begin given
involv small molecul eros curv could sever attent
eliqui ibranc given account two-third
cliff figur
eliqui composit matter patent due expir novemb
focu on-going proceed rule end
model assum gener entrant
impact base sale
headwind loe vs contribut year
look think visibl make gap loe
contribut notabl come abrocitinib vaccin franchis
 diff biosimilar growth etc beyond think need demonstr
de-risk across earlier-stag pipelin compani potenti proof-of-
concept studi read and/or pick pace busi develop
viatri deal close suspect upcom analyst day march
focu earlier stage pipelin mid-stag asset street
includ model
backdrop highlight number asset think critic
growth narr name four program critic updat next
month abrocitinib diff vaccin ibranc well vyndaqel launch
abrocitinib focu jade compar
pfizer first approv jak inhibitor xeljanz outperform expect grow
product outrun concern black box warn label
competit alway appear horizon back success
continu advanc jak biolog develop select inhibitor abrocitinib
importantli howev compani focus develop atop dermat ad
avoid cannib xeljanz
ad abrocitinib alreadi gener posit data two phase studi
figur less de-risk drug approv howev
critic question move forward commerci potenti drug street estim cap
upcom phase data read-out compar figur howev
provid head-to-head data may help dupix case regeneron/sanofi base
data profil weve seen date think challeng see drug
gener peak sale given rel high rate nausea
headach qd dose dupix head start ad like black-box
warn expect abrocitinib in-lin jak think dampen
vaccin prevnar franchis diff
vaccin prevent pneumococc pneumonia workhors
vaccin divis sale stabil around period
declin hold face merck inde prevnar benefit
option recommend use understand account
prevnar use
merck take aim part market develop vaccin
popul well adult immunocompromis patient merck
report posit phase data howev counter
vaccin includ seven addit serotyp beyond merck
head start skeptic manifest meaning shift share
trialsizestatuspopulationdesignprimari vs placeboiga respons week vs vs vs placeboiga respons week stat background topicalabrocitinib vs dupixentiga easi week background topicalabrocitinib vs placeboiga easi week /- background topicallong-term w/ option rescu treatment flaresabrocitinib vs placeboloss respons thru week barclay biopharmaceut
given advisori committe immun practic acip unlik chang
recommend immedi deepli entrench view
meaning enough advanc think maintain domin share
cdc recommend segment
clostridium difficil bacteri infect lead almost half million case
death unlik bacteri infect mump measl etc
approv vaccin diff backdrop poor track record
compani sanofi develop vaccin space understand street
larg ignor asset highlight uniqu vaccin structur modifi
toxin proprietari diagnost test logist expertis run studi earlier
clinic work defin optim vaccin schedul potenti across patient
hospit long period antibiot sever comorbid
market opportun quit larg though would built support
strong data drive acip recommend see high risk/high reward
opportun assign program probabl success lower standard
assumpt phase program given industri poor track record diff
sale opportun data phase clover trial expect
ibranc hold breath palla
pfizer inhibitor ibranc notabl stand-out compani sinc
approv metastat hr breast cancer maintain domin share across
class nrx/trx figur face competit lilli verzenio
novarti kisqali reach almost sale focu go forward
opportun adjuv set name outcom two studi penelope-
 palla read late earli respect figur
two palla commerci relev address larger
popul stage ii intermedi stage high-risk patient combin
endocrin therapi evalu two year ibranc therapi vs one year
penelop posit drug chanc success palla base
overwhelm efficaci metastat set solid learn phase
educ physician dose reduct vs discontinu good understand
placebo arm perform
data could support approv adjuv set drive doubl
address market ibranc support peak sale excess
modestli street vs street estim
compani report barclay research
ibranc hold domin share landscap
compani report barclay research
consensu estim alreadi reflect success adjuv
compani report barclay research
pfizer vyndaqel tafamidi transthyretin amyloid cardiomyopathi attr-cm
emerg relev driver peak better-than-expect launch
 roll-out benefit earlier expect approv april vs juli pdufa
broad label higher-than-expect price didnt appear limit access
street estim move consider sinc print print
price headwind due payor mix gross-to-net dynam drove
street number lower expect vyndaqel outperform
near-to-medium-term driven support dynam visibl grow
trialsizeset treatment year ibrancedfsdelay w/endocrin year ibrancedfsdelay earli sharemonthli nrxcdk nrxibranc share barclay biopharmaceut
diagnosi rate awar improv access trend solid contribut ex-u
upsid estim preval number
longer term see greater uncertainti time-frame compet
approach alnylam akcea eido potenti reach market
mn ou bn barclayscon feb rec chang commerci tafamidi chang price per pt chang barclay biopharmaceut
price target base price-to-earnings multipl base compani
fundament rel biopharma peer note deviat typic relianc
dcf due greater uncertainti around certain input remain
organ close mylan-upjohn merger expect
price-to-earnings analysi assum price-to-earnings multipl totalco ep estim
impli valuat assumpt support consider
compani growth profil top-lin growth flat ep loe overhang
also note would impli roughli multipl ep
remainco like emerg post deal close
risk rate price
upsid risk rate price target includ meaning bolt-on/busi
develop activ bring near-to-launch asset address upcom
posit diff data increas commerci attract therebi adopt
estim mid-year guidanc updat above-rang current consensu
downsid risk rate price target includ failur realiz cost save
upjohn separ failur execut separ neg ibranc data
adjuv set hinder likelihood reach peak sale dilutive/poor
busi develop activ fill upcom loe gap
inc quarterli annual ep usd
consensu number bloomberg receiv gmt
initi coverag regeneron overweight price target posit
regeneron outlook driven like near-term commerci out-performance
dupix eylea coupl libtayo optionaltiy dupix sale eclips run-
rate set-up strong estim vs consensu
contribut asthma adolesc atop dermat ad
launch broader ou roll-out despit partner sanofi recent peak sale
commentari barclay vs consensu remain
skeptic given competit threat competitor phase data ad
asthma high-profil event think misread see
either indic zero-sum given low biolog penetr said hiccup either
studi would posit sentiment street estim
expect program profit come better focu
improv overal margin follow rework sanofi collabor
report eylea demis greatli repeatedli exagger eylea sale
growth re-acceler street
sale vs note expect eylea consensu move follow
report vascul associ beovu treatment provid neg point
differenti rel approv vegf soon gaug full
magnitud impact beovu launch forecast eylea grow
result earlier stage longer-act option repres threat
time-frame sub-seg broader wamd popul think
diminish near-term concern provid compani time figur option
largest catalyst phase interim os analysi non-smal cell
lung cancer nsclc expect studi ultim support approv whether
studi get stop earli interim compar merck keytruda
benchmark overal surviv hr impact aspect initi
respons rate data look in-lin keytruda dont expect data chang
commerci dynam nsclc regeneron match approach keytruda
think would dramat shift investor percept around compani i/o platform
valuat risk pt base sum-of-the-part analysi compris
eylea dupix libtayo commerci product pipelin net cash
risk includ faster-than-expect eros eylea increas competit dupix
initi coverag regeneron overweight price target
despit pressur due drug price reform worri
fret competit threat eylea regeneron success eylea
growth re-acceler small feat product year market
dupix sale inflect higher new indic compani made solid
progress next wave pipelin asset co-stimulatori bispecif
expect least one two wave renew concern drug price reform
expect major legisl pass impact drug price run-up
elect like impli compani clear like longer
dynam coupl underli growth dme less compel label recent
concern vascul competitor beovu brolucizumab limit downsid scenario
next coupl year view would provid regeneron favor setup
continu growth eylea sale particularli expect dupix grow
present run-rat peak see potenti upsid eylea
dupix commerci perform well libtayo phase nsclc data
dupix libtayo pillar futur face near-term catalyst
commerci perform dupix provid encourag line sight
drug growth prospect near-to-medium term expect drug
run-rat relev competitor enter abrocitinib tezepelumab
headlin risk would argu well appreci forecast
toler regress efficaci earlier studi would read posit
signific attent reset convers drug like accret valu
compani broader i/o strategi think larg ignor investor
price target base sum-of-the-part analysi compris eylea
dupix libtayo commerci product pipelin net cash figur
risk includ faster-than-expect eros eylea increas competit
dupix clinic misstep libtayo nsclc
sensit analysi valuat
compani report barclay research estim
timingev catalystbarclay analysi os phase nsclc monotherapi studi high expressersw expect minim impact eylea compel dupix beat driven us prescript dynam ramp across mani countri resultsther lof skeptic libtayo match keytruda dataset long libtayo neightborhood result see net posit set libtayor combin regeneron asset vs near-term commerci stori lung cancer match beat keytruda would repres meaning upsid view guidanc re-work account jv dynam provid visibl improv margin top-lin abrocitinib jade-compar phase data abrocitinib vs dupi close rework sanofi collaborationth focu efficaci tolerabi profil abrocitinib lower-dos look undifferenti efficaci higher dose associ potenti untent rate nausea headach though notabl lower first phase dataset head-to-head compar data provid fuller answer barclay biopharmaceut
forecast peak sale short sanofi ceo peak sale guidanc
street consensu view built continu strong
adopt atop dermat ad strong initi uptak asthma ou roll-out still
earli day option layer addit indic street model
compet program advanc street awar asset high
impact least partial reflect street model dont view
zero-sum market particularli given ad asthma low rate biolog
penetr rel autoimmun indic singl digit teen percentag vs
basi acknowledg competitor take share also would
highlight area could benefit multipl player build market
what price
street consensu appear peak though poorli model
dupix layer growth begin pile
dupix sale grew drug exit year
run-rat alon figur commerci perform next two year
continu impress driven
continu growth ad includ first full year sinc adolesc approv ad
remain primari driver script iqvia data impli new prescript
written dermatologist importantli segment continu show solid growth
januari prescript vs januari
grow biolog penetr dupix share asthma look use
dupix allergist good though perfect proxi asthma
prescript illustr pace dupix adopt
driven biolog util higher short period time
addit ou countri come on-lin anoth underappreci point
dupix launch ou geographi still earli launch period
contribut ww dupix sale said look sale report global
iqvia data month decemb ou dupix sale alreadi
run-rat figur provid confid drug surpass
limit impact new commerci product phase data
expect abrocitinib tezepelumab regulatori submiss
expect earli respect impli minim impact
project dupix line extens approv year
regn dupix strong launch us ou
start
dupix driven spike biolog use allergist
ou sale volum strong
decemb figur imput novemb figur itali taiwan
portug due lack decemb data
competitor horizon also misunderstood
dupix launch fall alreadi handwring
emerg competit rinvoq phase data disclos interven
month dupix continu grow worri around competit entrant
persist emphasi focus oral jak inhibitor ad
ruxolitinib cream ad tezepelumab lilli lebrikizumab
undeni repres entrant could take share volum and/or mindshar think
threat dupix number vastli overst given size ad asthma
market sanofi recent set address patient unit state
low biolog penetr vs comp autoimmun diseas
suggest room entir market grow includ multipl entrant discuss
individu group
per dec vs growth barclay biopharmaceut
oral jak inhibitor introduct oral agent ad potenti attract
howev side effect paramount dupix inject also safe
toler beyond low rate conjunct view base kol
discuss dermatologist view phase olumi data limit
commerci perspect even consider drug baggag venou
thromboembol event rheumatoid arthriti suspect market
patient would prefer oral option vs bi-weekli inject dupix
think better option abrocitinib potenti jak inhibitor
like face challeng anticip fda continu use class label
 black box warn highlight risk infect thromboembol
abrocitinib earli phase data subsequ phase data show
differenti efficaci particularli nr chang measur itch reduct
dose lower dose look like non-start efficaci
discontinu rate decreas initi phase still potenti
unaccept rate nausea headach upcom phase compar data
head-to-head superior studi abrocitinib vs dupix provid
definit answer agent may competit posit abrocitinib
wide expect show better efficaci would argu bigger unknown
safeti profil discontinu rate remain higher dupix think
take away faster itch relief fraction patient
final phase data abbvi rinvoq also expect later initi phase look
outstand dose though fda approv dose ra
on-going phase studi explor somewhat cautiou
think far clear fda approv higher-dos ad vs ra
dermatologist would comfort use higher-dos rheumatologist ra
given respect risk toler profil indic specialti
efficaci across dupix oral jak studi
ruxolitinib cream develop cream formul ruxolitinib ad
contrast agent evalu moderate-to-sever ad
patient focus mild-to-moder patient view ruxolitinib
competit threat pfizer eucrisa run-rat
data true-ad studi expect form basi nda
submiss set approv late data phase true-ad
studi recent top-lin ruxolitinib cream achiev primari
secondari endpoint demonstr impress respons iga-t score
score investig global assess improv eczema area
sever index in-lin better seen dupix abrocitinib
far studi treatment-rel report compar vehicl
back data set approv
lebrikizumab recent gain right lebrikizumab antibodi part
acquisit dermira phase ad data appear roughli in-lin dupix
rais question point differenti potenti vs
dose expect file second phase studi read
support launch ultim expect lebrikizumab take share
around margin see product eventu reach sale mostli
due lilli commerci strength leverag exist footprint dermatolog
tezepelumab shortli initi phase data rinvoq ad report
impress phase data anti-tslp thymic stromal lymphopoietin antibodi
tezepelumab asthma tslp sit upstream dupix target potenti
offer broader activ phase demonstr profound reduct exacerb
irrespect eosinophil statu recal dupix benefit limit patient
moderate-to-high eosinophil level tezepelumab data roughli compar
data arent clearli apples-to-appl given eosinophil cut-off clearli
suggest broader efficaci tezepelumab though recapitul
phase navig studi data back strong phase data
phase wide expect readout posit major factor notabl lower
forecast asthma rel ad navig efficaci disappoint lack
differenti efficaci lower eosinophil patient see tezepelumab offer less
compel profil compet entrench competitor year
headstart market believ dupix would maintain high share
long-term forecast thought rework jv
model dupix sale grow reach
expect dupix hold major share ad market biolog adopt
reach adult high-singl digit popul asthma
model higher biolog util peak expect dupix stabil
low-to-mid rang figur
contributor estim
eylea eros curv look like
prior report beovu caus vascul expect dme growth would off-set
eros wet howev wake report vascul
reaffirm inflamm risk associ drug forecast eylea grow
inde continu view inflamm associ beovu
challeng faster adopt worst relev talk point regeneron
counter novarti see eylea eros hasten period
potenti entrant kodiak biosimilar either option drive share
nevertheless main take-away us see eylea remain growth
asset near-to-mid-term
street number volatil past two year driven combin
eylea out-performance near-term wave handwring beovu launch
street estim model flat sale eros sale though
would caution investor estim gener notabl sell-sid
consensu topic
eylea re-acceler growth set stage
step growth novartiss beovu horizon
consider handwring futur eylea posit wet
dme paradigm regeneron top-lin forecast stabil growth trend
re-acceler sale growth impress feat brand howev
show dme adopt still power growth forc actual wet
show market growth well despit claim satur
expect eros eylea share launch beovu
next page emerg vascul case dampen pace beovu
adopt wet base forecast eylea sale grow
wet dme indic forecast seen vs
consensu figur
crosswalk eylea estim
beovu launch one close watch narr across sector
next coupl year one point came present phase
dataset drug intraocular inflamm rate
novarti dismiss differ arm safeti subsequ disclosur
eylea arm rate beovu label brought point forefront
later februari case retin vascul includ case design
occlus retin vascul could threaten patient vision report
percentag appear small context ten thousand inject
remind investor even differ inflamm rate commerci impact
recal earli regeneron saw increas rate inflamm believ
due impur manufactur process small bump neg impact
sale importantli deterior sentiment sher backdrop
expect signific commerci pushback near-term beovu potenti
longer risk better character could take time
even advanc updat feedback recent angiogenesi meet well
gener feedback kol suggest drug rate inflamm
recur topic discuss might limit beovu adopt
beovu inflamm rate notabl higher eylea despit fewer inject
mix take long-term threat eylea
beyond on-going launch beovu emerg threat eylea busi
model eros intensifi model massiv reset
one year skeptic introduct biosimilar meaning shift eylea share
given price-sensit part market patient avastin today alreadi
option avastin think greater threat longer act agent howev
see high bar safeti profil may approach semi-annu
treatment order better enough exist option retin specialist
accommod disrupt product practic econom
government action drug price remain headlin risk
eylea crosshair much drug price polici debat
given reimburs primarili medicar part given affect
popul notabl price differenti eylea ou eylea
bayer manag expect anoth wave two headlin risk around drug price
balanc howev think rel lack inact sinc last summer
essenti rule action presidenti elect like
linger question timelin implement think investor larg
comfort view impact prior remot
what price
option valu libtayo nsclc data
potenti meaning move share estim merck keytruda
clear domin winner across front-lin non-smal lung cancer nsclc libtayo
match data high express would open strateg
option regeneron rang launch lung enhanc compani
confid around abil compet libtayo backbon variou
combin strategi given merck headstart lung assum regeneron would
launch drug commerci lung monotherapi metastat lung though
like would still pursu approv nevertheless still import strateg valu
think might impact libtayo posit around combin
potenti monotherapi option broadli adjuv put number
valu straightforward think one way think keytruda drive
merck valuat conserv data alon could provid path
unlock valuat assum lower-end rang
probabl libtayo os data roughli compar keytruda see
potentiallym worth regeneron risk-adjust data
compar expect regneron would provid updat thought
clinic
develop strategi leverag data
minim share sinc initi interim press releas libtayo earli
novemb though note share move meaning day press
releas overlap compel eylea beat subsequ updat
failur etokimab catalyst next move base
stock reaction see increment valu assign lung data
libtayo approv cutan squamou cell carcinoma cscc mark
approv fda irrespect order regeneron initi focus
non-melanoma skin cancer provid sourc differenti rel
agent strategi allow compani get foothold market
effort name studi lung cancer combin approach
focu nsclc os read-out benchmark
novemb regeneron report interim data phase nsclc studi
libtayo vs chemotherapi patient express interim data cut
libtayo show benefit vs chemo overal respons rate vs rel
compar keytruda data vs encourag
main focu drug benefit overal surviv compar
reduct risk death seen hr high bar complic
shift standard care europ importantli unlik bristol
studi read-out libtayo need get close data
necessarili better drive home point libtayo rival upsid unlik
scenario beat data would drive upsid
benchmark libtayo high express nsclc
price target base probability-adjust net present valu sum-of-the-
part npv sotp analysi compris eylea us ou revenu bayer
dupix inclus origin sanofi collabor product praluent
kevzara libtayo well risk-adjust valu option lung
earli stage pipelin net cash
assum weight averag cost capit wacc assign termin
growth eylea
sensit valuat driver
compani report barclay research estim
risk price rate
downsid risk price target rate includ faster-than-expect eros eylea
progress drug price reform price increas
competit dupix inabl dupix garner line extens disappoint
data and/or better expect data bispecif
inc quarterli annual ep usd
consensu number bloomberg receiv gmt
initi coverag acceleron overweight price target acceleron
uniqu posit across smid-cap biotech meaning econom one
blockbust process launch reblozyl peak sale estim
second wholly-own asset sotatercept meaning de-risk
potenti complementari therapi estim space
pah pulmonari hypertens context view sotatercept peak
sale potenti pah inde posit top-lin sotatercept pulsar studi late
januari transform narr set multipl import updat
balanc pulsar present may spectra hemodynam data
updat regulatori strategi reblozyl launch gather momentum
hit acceler pulmonolog franchis acceleron disclos bare minimum
term statist pulsar hit statist signific across pulmonari
vascular resist pvr walk distanc nt-probnp chang
function statu unparallel heavili treat popul patient
triplet background therapi present data like at may crucial
size robust effect alreadi appear robust novarti
gener imatinib without safeti drawback still see potenti
acceler approv dataset depend upon efficaci seen patient
triplet therapi could acceler pah franchis also wouldnt rule
strateg busi develop add asset pulmonari recent
collabor fulcrum cover build threapeut area leadership
consist ceo vision convey back
upsid reblozyl estim reblozyl see straightforward approv subgroup
md patient rs earli april continu see upsid street
number given unappreci durat dynam near year sweet-spot
like md label well physician patient percept clinic benefit in-
line modestli reblozyl sale barclay vs con
notabl sale vs consensu long-term see
peak potenti vs consensu
valuat risk price target base sum-of-the-part analysi
includ risk-adjust contribut sotatercept pah reblozyl
risk includ disappoint data pulsar present pah delay
setback reblozyl clinic timelin pushback reblozyl price poor access
emerg competit reblozyl md and/or myelofibrosi
initi acceleron overweight rate pt
acceleron becam public back leadership posit tgf- biolog
valid partnership celgen luspatercept/sotatercept exactli
asset continu drive narr today luspatercept reblozyl
approv one indic soon approv second peak sale
potenti sotatercept back wholly-own acceleron also de-risk
data pah multi-billion sale potenti own-right clinic updat pulsar
spectra clariti regulatori path phase strategi sotatercept
keep investor engag earli attract pah well
appreci street though think complementar sotatercept exist
therapi overal lack competit come greater focu acceleron
outlin clinic develop strategi timelin bigger pictur de-risk
sotatercept put rest bear argument simpli reblozyl royalti stori
limit strateg attract acceleron
reblozyl estim appropri room upsid
think reblozyl larg get pass report number launch dynam
get print md approv set earli april emerg
predomin driver sale worri see demand product today
suggest despit limit month dose consensu estim
like fine rather focus ramp evolut
durat real-world take time get handl
deriv price target base npv sum-of-the-part analysi figur
compris sotatercept pah po reblozyl individu
po assumpt assum approv md occur
broader pipelin net cash assign zero valu use
discount rate base standard assumpt commercial-stag smid-cap biotech
assign zero termin valu program also stress-test assumpt
sensit analysi npv calcul
monitor thesi track follow potenti catalyst figur
timingev catalystbarclay reblozyl ema md pdufatop-lin data cmtstraightforward approv expect label anemia low-to-intermedi rs md patient requir tranfus neg result data wide expect readout neg failur expect minim impact peopl focus sotatercept data bristol earn call close monitor insight reblozyl uptak md consensu estim sotatercept pulsar data pah at data alreadi known posit focu magnitud benefit clinic benefit patient tripl background therapi commentari regulatori strategi whether compani alreadi meet fda phase spectra data evalu sotatercept effect hemodynam paramt pahgiven spectra open-label anticip data could share fda part meet time expect updat regulatori strategi data disclos ema decis reblozyl applicationtop-lin reblozyl data beyond studi non-transfus depend beta-thalposit data support broaden label ntd beta-th patient barclay biopharmaceut
sotatercept incorpor pah paradigm
like broadli depend upon final data pulsar subsequ develop
pivot studi howev concord statist signific benefit pvr
nt-probnp chang function class power start orthogon
mechan like complementari variou vasodil struggl find reason
wouldnt ad exist option particularli patient move beyond oral
background therapi mind model peak sale potenti
note at dataset may critic provid sens potenti
posit paradigm potenti regulatori strategi includ acceler
approv patient alreadi background triplet therapi
share gain back posit phase sotatercept data
street assign increas increment valu potenti revenu
pah well increas compani strateg attract wholly-
own second valu driver basi think street larg price
potenti revenu sotatercept suggest posit later line line
agent modest option around move earlier line therapi
background sotatercept pah
pulmonari arteri hypertens pah progress fatal diseas character
endotheli dysfunct progress remodel distal pulmonari arteri lead
elev right ventricular systol pressur right heart failur current treatment
paradigm center vasodil via variou mechan though may
improv exercis capac delay time clinic worsen correct
underli diseas mechan revers pathogen remodel consequ pah
mortal rate remain high half patient die within five year diagnosi
sotatercept ligand trap activin member tgf- superfamili believ play
mediat role tissu remodel associ pah activin upregul
pah suppress signal pathway known play key role
myogen fibrogen differenti vascular homeostasi herit form
pah trap activin sotatecept believ restor bmp signal normal
physiolog level potenti revers associ remodel
basi find herit pah data across pre-clin model well
data imatinib phase studi pah acceleron pivot program pah upon
re-obtain right drug celgen exchang downstream econom
sotatercepet clinic develop program compris two studi pulsar
pulsar six-month phase studi design evalu sotatercept impact
pulmonari vascular resist pvr vs placebo background therapi addit
endpoint also explor complement pulsar phase
hemodynam studi spectra expect read-out spectra
util cardiopulmonari exercis test cpet evalu chang exercis capac
cardio magnet reson imag mri evalu hemodynam paramet
chang stroke volum end-systol volum
sotatercept clinic develop program pah
take pulsar phase data
posit phase data report januari view de-
risk given appear heavili treat popul
background tripl therapi statist signific benefit pvr nt-
probnp chang function statu
key focu point forthcom present like american thorac
societi at meet may
magnitud chang pvr match imatinib
data placebo-adjust reduct pvr well absolut
improv baselin placebo-adjust basi
subgroup-analysi patient triplet background therapi show
improv vs placebo popul
impact pvr patient background oral therapi
confirm safeti profil
expect compani go fda spring end-of-phas meet
base data whatev data open-label spectra studi
vs chang week posit top-lin report jan sig improv pvr nt-probnp data present like at singl chang week data expect barclay biopharmaceut
time come meet gain clariti phase develop
strategi street larg expect compani move phase pivot studi
like take year complet wouldnt rule potenti acceler
approv top triplet background therapi particularli data compar favor
recal novarti went regul time-frame data
approv pah scrap idea regulatori ask data
howev would point pulsar dataset triplet therapi
vs fda evolv toward significantli accommod
postur sinc sotatercept lack worrisom safeti issu bleed
hematoma seen imatinib set base case
would surpris play way
comparison pulsar histor imatinib uptravi ralinepag data
think commerci potenti sotatercept pah alreadi brand
market world-wide basi key messag sotatercept potenti
complementari exist agent space differenti mechan
focus vascular remodel orthogon approv vasodil
potenti sotatercept combin exist agent initi view
sotatercept would take gradual process move sequenti line therapi
begin line agent think compani actual lot
option regardless see clear use drug line upon approv
also expect make inroad earlier line therapi
model ww peak sale base peak adopt us/ou
oral background therapi regardless combin model net price
annual annual ou
class class class class pvr rel placebochang bl rel placebo chang function classimatinib-uptraviralinepagpulsarimpresgriphonphas differencend gmr nd week week ls barclay biopharmaceut
compani report barclay research estim
reblozyl surpass consensu
ye think opinion street persist under-model number
patient deriv clinic benefit result like stay therapi
potenti durat therapi see point like bump durat drug
move earlier lines/less-transfusion-depend patient model peak sale
driven primarili md contribut beta-th
myelofibrosi expect continu updat medalist coupl
initi real-world experi shift debat point look forward
street consensu forecast reblozyl sale look
consensu forecast reblozyl sale md
beta-thalassemia myelofibrosi
reblozyl support matur acceleron
reblozyl luspatercept discov initi develop acceleron
partner celgen jointli develop commerci drug celgen book sale
acceleron receiv low royalti potenti downstream mileston
reblozyl ligand trap select specif member cytokin
transform growth factor-beta tgf- superfamili known
neg regul erythropoiesi step-wis process red blood cell
gener ineffect erythropoiesi manifest anemia clinic develop
luspatercept priorit indic anemia hallmark
compris low-risk md beta-thalassemia myelofibrosi mf posit phase
studi transfusion-depend beta-thalassemia believ subset md patient
medalist reblozyl approv beta-th late wide expect
approv md april pdufa date
look commerci launch reblozyl street peak sale
estim see number key driver believ street continu
underappreci outlin follow page
support durat dynam misunderstood definit clinic benefit like
target popul launch vs phase design
potenti upsid epidemiolog estim
vs eporbc-ti expect late vs pborbc-ti april data vs pbohb chang data expect open-labeltd vs pbopk/pddata expect vs pbohi-eapprov w/ jak txtbdreblozyl vs epotbdstudi start data barclay biopharmaceut
durat remain underappreci driver
reblozyl durat key driver revenu potenti drug support continu
clinic benefit defin physician broadli transfusion-independ
excel toler see june note durat durat durat link
inde durat peg back look pretti much spot
recent updat walk coupl key point term
think durat
physician defin clinic benefit broadli transfus independ
consider focu disappoint
transfusion-independ rate rbc-ti achiev reblozyl vs
placebo medalist median durat week across respond matur
data show median durat week across rbc-ti respond
remind investor howev rbc-ti regulatori endpoint measur
physician patient think clinic benefit view use erythroid
respons like better gaug clinic benefit even clinic benefit could
view lenient use rbc-ti and/or hi-e hematolog improv
erythroid clinic benefit seen medalist notabl higher
less heavili transfus segment next bullet
treat patient popul like evolv toward less prior transfus studi
popul studi medalist artifact lack treatment option post-esa
erythropoiesis-stimul agent posit regulatori agenc around
endpoint rbc-ti reblozyl soon avail expect physician persist
long transfus turn reblozyl net impact would
expect profil patient start reblozyl near-term increasingli
lower/no transfus burden use immedi esa current
label import clinic benefit drug either defin either
rbc-ti broadli better lower transfus burden durat
clinic benefit extend closer two year less heavili transfus
popul figur point explor
updat medalist larg overlook
safeti remain excel
low discontinu rate given age
concomit condit studi popul patient discontinu
therapi vs placebo speak toler
subgroup analysi datacut
final word durat
given consider model defin respond achiev
clinic benefit would argu patient think
conserv given patient lower transfus burden achiev benefit
model month durat across patient achiev respons non-
baselin transfus requir studi population-ti -ti hi-e durat clinic benefit week subgroup achiev barclay biopharmaceut
respond model three month durat note addit month durat
md translat increment ww sale peak
payor data suggest upsid epidemiolog estim
standard sourc epidemiolog oncolog indic nation cancer institut
seer databas peg md incid preval respect
number notabl differ kol commentari inde claim analysi
space suggest seer may meaning underestim epidemiolog
note seer dataset driven registry-bas approach input come
hospit report md diagnos howev given ubiquit symptom
low-risk md particularli elderli diagnos made commun
oncologist offic set get captur seer impli like
underreport actual diagnosi rate three retrospect cohort review payor
claim data indic incid md may fall rang
contrast seer estim import look
launch preval pool patient regular blood transfus
progress esa
lack progress keep posit incent
luspatercept administ via subcutan inject healthcar profession
physician offic md indic primarili cover patient medicar median
age medalist year old import drug cover
medicar part allow prescrib reimburs averag sell price plu
asp assum dose list price per cycl gross-to-net
discount would impli oncologist offic would increment revenu
opportun per inject like administ nurs physician assist
per patient per year commun hematologist-oncologist whose
incom link econom practic would provid mean revenu
stream would align appropri care practic think lead less
watch wait abandon esa earlier less toler red-blood cell infus
zero neg margin opportun practic
larger debat drug price polici reform propos might
elimin lower reimburs physician administ part drug
effort essenti stall expect favor incent remain
place least provid acceleron import tailwind launch
forecast peak sale reblozyl driven primarili md
contribut beta-th myelofibrosi detail assumpt
summari number shown figur estim vs consensu shown
summari luspatercept forecast
consbmi salesmd b-thal- myelofibrosis- othertot reblozyl us sale mn eu salesmd b-thal- myelofibrosisothertot reblozyl ou sale mn total reblozyl ww sale mn royalti tranch tranch tranch royalti mn barclay biopharmaceut
share ytd vs nbi februari respond
posit pulsar data late januari drove share
follow choppi octob time-frame stock ralli
updat new year anticip pulsar data
valu acceleron assign pt base sum-of-the-part sotp analysi
compris valuat contribut sotatercept reblozyl modest
valu remain pipelin net cash forecast
sotatercept reblozyl extend project patent expiri base
combin disclos ip like patent term pediatr extens consider
biosimilar compani abil replic product calcul project
cash flow acceleron base project royalti rate estim margin tax rate
risk-adjust forecast view program probabl success
share perform jan feb
npv sotp analysi share
 datareblozyl bla filedreblozyl beta-thalapprovedasset indicationposnpvp sharereblozyl md md b-thal ntd- b-thal pipelin net total outstand rate tax barclay biopharmaceut
risk price target
downsid risk price target includ
clinic risk still weight toward clinic develop acceleron expand portfolio
risk includ setback clinic timelin reblozyl sotatercept lack
quantit data support initi top-lin readout unclear phase strategi
regulatori risk reblozyl md indic still review fda eventu
applic mf sotatercept pah risk approv and/or increas regulatori
requir could burden acceleron timelin strategi
commerci risk poor payor access delay launch time delays/chang
celgen partnership could impact near-/long-term sale estim disadvantag
reblozyls/acceleron commerci posit ahead competit
inc quarterli annual ep usd
consensu number bloomberg receiv gmt
initi coverag overweight pt development-
stage biotech differenti approach address neurodegen diseas
leverag immun system focus targets/popul inform valid
human genet balanc share posit benefit
four clinic readout potenti valid compani platform
scientif thrust well begin shift street view compani early-
stage play novel scienc late-stag product-driven stori address indic
underappreci commerci dynam frontotempor dementia ftd
inde given dynam coupl think like favor shift
across regulatori landscap neurodegen diseas view share
offer one attract risk/reward coverag univers
phase infront data risk/reward skew posit phase ftd updat
provid de-risk back initi phase evid target
engag benefit biomark base case drug show
clear benefit serum neurofila encourag trend brain atrophi drive
share higher think street underappreci commerci dynam
ftd could see grow market potenti fda
acceler approv bullish phase scenario scenario
shot alzheim diseas ad alector
program respect earli proof mechan biomark
data alzheim patient given clinic risk alzheim coupl
small sampl set trial lower expect
clear signal emerg read-out net-net see data provid upsid
option beyond ftd keep investor engag particularli fda take
accommod stanc approv aducanumab ad
valuat risk price target base npv sum-of-the-part analysi
compris ftd alzheim
assign platform valu net cash forecast risk-adjust sale
ftd probabl success po grn mutat po
mutat assum launch first grn follow
peak us pos-adjust sale unadjust use discount rate
in-lin standard assumpt ahead de-risk phase data
initi overweight rate pt
last year februari differenti approach
neurodegen diseas stark contrast focu player space
misfold protein alon center effort leverag brain immune-
system address multipl patholog neurodegen diseas
backdrop coupl perceiv early-stag natur program
surpris stock larg view option novel scienc rather
strong focu individu product opportun think dynam shift
driven critic phase readout compani lead asset multipl
asset gener clinic data alzheim togeth data allow investor
easili assign valu vs platform stori drive share higher
eye updat ftd commerci dynam underappreci
phase compani higher profil clinic catalyst date
potenti reset investor percept posit data minimum support
compani approach toward neurodegener move phase best
posit data could support file acceler approv move share
think ftd underappreci commerci potenti peak sale
potenti given attract price long durat like shift epidemiolog lack
compet option lack impact biomark would perceiv neg
though think that lower probabl event given phase target engag
biomark data
 addit option mid-stag alzheim asset
alector program respect initi
phase data read neither program explicitli street model
proof concept data could support move phase drive
investor ascrib valu
price target deriv base npv sotp analysi
forecast risk-adjust sale ftd program patient grn mutat
po assum potenti launch grn mutat first
po ad program forecast risk-adjust sale probabl
success commerci initi market entri begin also
includ valu platform net cash use discount rate
drugtargetpopulationstagepartnerftd-grnphas indic -- -not includ model barclay biopharmaceut
timingev catalystbarclay bla submiss aducanumab alzheim diseasew expect submit fda accept think potenti prioriti review would posit read-through potenti biomarker-driven regulatori strategi across neurodegen alzheim present ad/pdlook updat on-going phase program and/or preclin ftd phase updatew expect top-lin readout phase data ahead present ftd data presentationfollow top-lin updat mid-year expect present phase ftd data six-month follow-up includ brain vmri data biomark data end-of-phas meet fda ftd clariti regulatori strategi ftd patient barclay biopharmaceut
infront mid-year updat de-risk
ye think posit bias mid-year readout phase infront
studi given compel causal relationship ftd grn mutat clear
evid target engag seen preclin clinic biomark data think
improv like improv vmri improv
either would increment de-risk head phase concord biomark
data benefit cognit could drive acceler approv
ytd think appreci increas share risen ytd vs
nbi feb like reflect construct take broader platform approach
still reverse-engin model estim po assign
background
alector lead program monoclon antibodi direct sortillin
protein develop treatment genet defin sub-
segment frontotempor dementia ftd transmembran receptor
involv progranulin pgrn degrad pathway inhibit
aim increas concentr pgrn figur ftd rapidli progress
neurodegen disord character chang behaviour person and/or
languag aphasia driven degener frontal and/or tempor lobe
diseas often consid early-onset dementia symptom typic surfac
specif sub-popul ftd mutat grn caus low level physiolog grn
progranulin involv modul optim microgli function critic diseas
like ftd microgli dysregul contribut damag neuron mutat
one two grn allel lead greater decreas pgrn level figur
caus ftd patient greater probabl causal relationship
increas confid rais pgrn level like lead clinic benefit
patient grn mutat could potenti show benefit ftd patient
block sortilin degrad pathway
pgrn defici link ftd ftd-grn mutant
take ftd
posit bias program base view compellingli
relev biolog progranulin level ftd across pgrn mutant patient select
strategi clear evid target engag demonstr thu far peripheri
 blood cerebrospin fluid csf program move toward phase data
readout emphasi biomark data serum neurofila data volumetr mri
inform next step toward clinic develop potenti
regulatori strategi phase enrol grn mutat patient subgroup
updat expect present fall phase
also anticip start
point see three critic question assess program
mechan relev ftd think least patient
mutat progranulin gene causal relationship heterozyg
mutat grn ftd strong penetr compel revers
progranulin deficit observ multipl anim model pgrn increas addit
take encourag extern player wave life scienc
cover advanc progranulin target candid clinic
drug penetr brain relev concentr mayb impress
concord target engag data downstream effect serum csf
pgrn level across mice non-human primat nhp healthi volunt initi
set ftd-grn patient said dont think data weve seen thu far
conclus demonstr adequ brain penetr drug entri csf
trialpopulationsizestatustakeawaysphas safe well toler demonst target engag block tripl pgrn level serum doubl csf phase safe well toler increas plasma csf pgrn concentr hv level demonstr decreas vs baselin snfl levelsphas ftd-grn focu nfl vmri long-term follow-up ole provid sourc addit catalystsphas start primari endpoint plu nacc ftld-sb addit biomark inlcud nfl vmri bayesian design incorpor multipl opportun interim analys barclay biopharmaceut
measur blood-brain barrier bbb permeabl though referenc
clear relationship csf biomark level brain target engag non-
human primat studi find encourag
acknowledg evid literatur albeit mous model
jackman et al neurosci dec blood-brain-
barrier may impair ftd much evid across neurolog
disord may facilit better brain penetr typic
serum filament biomark data decreas three month across five
patient none patient saw increas provid anoth set evid
drug may penetr brain given biomark link axon injuri sever
ftd rate increas would normal project three-month
period howev data complic somewhat fact three
addit patient phase exclud analysi albeit look like
doubl csf pgrn level volunt
doubl csf pgrn level ftd patient
biomark chang serum nfl volumetr brain mri predict
clinic outcom think appropri biomark given correl
diseas symptom ultim data clinic outcom need gener
justifi adopt see enough support biomark justifi
acceler approv certain scenario
view phase inform readout
phase readout expect fall potenti outsiz impact
compani share thought help defin potenti scenario
order better assess investor may react data defin scenario
high level think point help keep mind
small sampl size rel small sampl size would focu
ftr-grn segment patient
avail histor control data unlik mani diseas street actual
histor data chang biomark clinic outcom ftd
enabl street investor alik readili interpret benchmark data
focu biomark vs cdr-sb data given small size rel limit
follow-up would expect see impact cdr-sb six-month mark
flip-sid benefit cdr-sb point would highli stock move
scenario analysi phase inform ftd-grn subset read-out
separ also pursu next-gener target antibodi broader
neurodegen diseas alzheim parkinson diseas current
exclud model success would read-through
program compani broader platform initi proof mechan data phase
expect though expect data greater impact
us preval ftd eu grn mutat account
ftd case inherit ftd translat us
eu preval similar also geographi
pharmacolog intervent exist ftd treatment limit support care
address associ symptom antidepress antipsychot
ftd-grn program advanc rapidli phase expect start year
given greater understand ftd grn mutat conserv
see greater use popul pend data model peak
penetr ftd-grn assum ftd-grn
case diagnos support symptomat treat base
case assum studi run complet top-lin data file
launch follow model launch
estim unadjust us net sale peak sale
assum price in-rang rare diseas therapeut area
approv agent exclud patent extens patent expiri
henc dont expect gener entri earliest
scenario monthli vmri mo cdr-sb mo stock reaction like upsideimprov vs baselineminim chang vs baselineani benefithighli posit would support acceler approv particularli confirmatori phase underway posit read-through platform baseclear benefit vs histor controlsom benefit vs histor controlsno benefitmodestli posit though depend upon magnitud cadenc chang like rais stake around month updat still support move phase downsideno benefitno benefitno benefitneg would rais question target engag brain penetr decis advanc phase move might otherwis mitig upcom ad read-out datalarg point nfl level increas fold year suggest dramat increas diseas natur histori ftd patient typicallli lose brain volum per year cdr-sb show linear decreas week histor control barclay biopharmaceut
eu model sale assum launch
price discount us think commerci partner like
assign flat royalti rate
ftd-grn popul us ftd populationp pgrn incidencep end address grn penetr patient tx- net annual price grn sale mn popul incidencep end address penetr patient tx- net annual price sale mn barclay biopharmaceut
ftd-grn popul eu ftd popul pgrn incidencep end address grn penetr patient tx- net annual price grn sale ou mn popul incidencep end address penetr patient tx- net annual price sale ou mn barclay biopharmaceut
 demonstr proof concept
mayb though phase data limit safeti biomark minim valu
howev assign share program suggest low downsid skew
data turn uninspir though case could made given scienc
behind compani approach toward engag microglia massiv
commerci potenti alzheim two shot high-risk/high-reward upsid
readout year
littl valu bake either program like driven implicit
tackl alzheim immuno-neurolog
alector approach tackl neurodegen diseas base compani
underli philosophi diseas driven failur immun system
view support genom wide associ studi gwa indic
top mutat link alzheim diseas associ microgli
function leverag find focus develop antibodi impact
microglia counteract mutat addit compani approach leverag
biomark inform develop verifi mechan action facilit reach
proof concept advanc long-term clinic outcom alzheim specif
focus initi two key target siglec
relev microgli function inflamm dont see direct
implic alector program recent failur dian-tu eli lilli
roch evalu patient genet mutat ad specif autosom
domin ad mutat adad particularli weve seen last six month
ad program must evalu merit
push/pul microglia ad
monoclon antibodi direct transmembran receptor
express brain microgli critic microgli cell migrat
note insuffici activ risk factor ad patient homozyg
mutat go develop dementia heterozyg mutant
greater risk rel broader popul design optim microgli
function boost activ decreas shed specif
expect stimul greater microgli function well support surviv
prolifer microglia
monoclon antibodi direct siglec inhibitori cell surfac
receptor express microglia associ risk variant ad contrast
activ siglec slow microgli activ reduc myeloid
function potenti slow uptak amyloid beta importantli clinic develop
run parallel
preclin phase data support mechan
preclin data data initi phase trial support encourag
follow point
effect target engag reduct nhp hv preclin
data non-human primat nhp demonstr profound decreas
concentr csf dose corrobor
dose-depend reduct healthi volunt max
reduct baselin highest dose evalu
increas microgli activ preclin data mice demonstr signific
increas microglia prolifer mice recruit microglia plaqu
mice reduct plaqu coverag mice increas microgli
biomark activ seen nhp healthi volunt nhp
healthi volunt note howev exact ident biomark
disclos altogeth data provid encourag initi evid drive
intend increas microgli function
sign cognit benefit vivo model mous model ad treatment
mous version demonstr statist signific
improv novel object recognit test memori test water maze
safeti issu character safe well-toler phase
phase proceed thu far without issu
preclin phase data support mechan
preclin data thu far demonstr durabl dose-depend target
engag singl inject similarli observ phase
healthi volunt studi higher dose significantli downregul
siglec cell surfac virtual elimin receptor effect sustain
sever week potenti allow extend dose note data
biomark analys monocytes/peripheri state could translat
microglia level indic preclin studi
note howev highest two dose test eight demonstr drug-
relat sae ultim resolv follow steroid administr
determin taken forward phase
what
data phase studi mild moder alzheim patient
expect studi evalu safeti
drug vs placebo though biomark assess csf biomark mri scan also
evalu allow assess pk/pd csf well
potenti insight drug penetr brain impact plaqu alector
alreadi announc plan start phase high-level thought
blood csf imag biomark well cognit measur assess
potenti take program phase opts-in
trigger up-front equiti payment well shift
develop cost
model program one combin alzheim program
revenu build npv analysi
initi phase data expect anticip move
phase earlier set data time-frame model
potenti launch europ
defin address market us eu launch base
us/eu diagnosi treatment rate respect
model us eu peak penetr acknowledg meaning uncertainti
number therapi might reach market may
integr paradigm potenti magnitud benefit might impact
adopt rate given earli stage natur program challeng track
record alzheim drug develop assign po combin program
translat valuat
 revenu build preval total treat net annual price sale royalti due econom revenu build preval total treat net annual price sale mn royalti due econom mn barclay biopharmaceut
share price ipo februari volatil
trade wide rang thu far share outperform
ytd vs nbi reverse-engin model base current share price
think street assign roughli po stub valu
rest pipeline/platform
assign pt base sum-of-the-part sotp analysi compris
valuat contribut assign
valu platform net cash reflect pro forma cash posit
valuat driven ground-up revenu forecast
estim margin risk-adjust base view probabl success
express percentag defin success commerci
assign probabl success ftd-grn
model bla file ftd-grn launch phase data
readout encouragingli see path toward acceler approv move
timelin year launch conserv assum launch
exclud indic al broader ftd base valuat analysi
assess program collect purpos
valuat po still earli stage challeng track
record alzheim drug develop
sensit valuat driver
risk rate price
downsid risk rate price target includ pipelin clinic trial failur
emerg advers safeti event lead pipelin product delay clinic trial
timelin chang partnership emerg new therapi ad
alter scientif clinic commerci relev alector product addit
remain risk potenti price assumpt ftd ad potenti
pushback patient physician payor and/or govern
po ftd -grndiscount rateassetpo totalp indic -- -not includ model barclay biopharmaceut
allako inc quarterli annual ep usd
consensu number bloomberg receiv gmt
initi coverag underweight price target single-
drug biotech priorit develop infus antibodi antolimab across
eosinophil gastrointestin diseas egid market cap north follow
phase data report last august sell-sid adjust peak consensu
current level impli high-level commerci clinic success priced-in despit
pertin question size target market competit compani
largest target market eosinophil esophag eoe see competit dataset emerg
threat potenti posit antolimab see better runway
eosinophil gastritis/gastroenter eg/eg dont see market
support commerci valuat attract strateg player remain
opportun mast-cel driven diseas indic need de-risk
also commerci valid meaning street estim peak
clinic differenti eoe unclear add challeng commerci setup
antolimab clearli distinct approach rel biolog target eosinophil
driven diseas clinic impact eoe appear rel undifferenti phase
dupix data phase data dupix phase data fasenra
come focu balanc rais debat antolimab
potenti eoe inde see drug entrench commerci presenc
valid activ overlap co-morbid well potenti emerg oral
agent arena etrasimod bristol crowd play field
multi-hour infus product antolimab
dermira case studi inform recent acquisit dermira eli lilli provid
inform case studi situat similar dermira lebrikizumab
view undifferenti face steep competit approv agent
includ dupix emerg oral option despit dynam intern
estim call peak sale dermira sold even
consid atop dermat asthma valid commerci market vs
egid need built ground see speak
valuat risk assign price target base probability-adjust
forecast antolimab across eg/eg po eoe po
plu project net cash risk thesi includ setback
compet product abil secur price estim
interest compani asset strateg player see next page
initi coverag underweight price target
focus leverag understand biolog develop
modifi antibodi antolimab potenti applic across rang
autoimmun inflammatori condit challeng face howev
field seen explos agent antibodi tslp antibodi jak
inhibitor inhibitor advanc differ paradigm gradual address
larger commerci attract indic asthma atop dermat that
say antolimab doesnt potenti indic challeng
busi proposit compet small biotech
backdrop highli strateg develop choic
focus opportun biolog particularli relev well
indic mast cell inhibit compon antolimab may impact
priorit set indic includ egid larg ignor
recent pharma biotech demonstr clear proof-of-concept phase
studi across eg/ege/eo justifi move phase view howev critic
question center commerci attract indic context
increas evid establish player encroach upon indic inde
alreadi evid grow effort eoe commercially-relev see
antolimab like disadvantag given mode administr subcutan
inject oral vs multi-hour infus proven efficaci agent
overlap comorbid may push payor away agent arent allow
address manifest one agent entrench presenc
allergist commun eg/eg like provid better runway antolimab target
address market like fraction preval sign interest
across biotech expand agent market see signific commerci
risk rel what price share today
see point critic relev discuss drug strateg
attract extern parti see immunolog inflamm
space remain focal point mani biotech howev recent dermira acquisit eli
lilli underscor view unwilling pay given signific commerci risk
amidst question differenti attract may evolv
compani execut subcutan formul potenti de-risk mast
cell driven diseas expect ration impli commerci potenti
antolimab eoe
price target base probability-adjust forecast antolimab across
eg/eg po eoe po plu project net cash
risk thesi includ emerg evid mast cell inhibit drive
drug efficaci disappoint result delay biolog space abil
secur price estim acquisit strateg
timingev catalystbarclay phase meet w/fda delin takeaway meetinginiti phase eg/eg phase eoe studi start scheduletop-lin data phsae open-label studi data subq antolimablik import updat see iv form commerci viabl relev compeitiondata part dupix phase eoe studygiven open-label design compani messag surpris data posit interest chang clinic develop strategi expect blind placebo-control efficaci data dupix vs placebo week data eosinophil reduct chang dysphagia symptom questionnair data long-term extens compon enigma eg/egefocu durabl respons sinc chronic diseas focus long patient stay studi evid diminut respons time barclay biopharmaceut
antolimab achiev consensu sale
unlik model peak sale driven primarili eg/eg rather eoe
given strong competit view phase data de-risk eg/eg
encourag initi proof-of-concept eoe howev think market misread
drug commerci potenti given lack differenti eoe compet agent
offer better deliveri least proven efficaci overlap comorbid
like lower price rel street assumpt antolimab risk thesi
includ egid market end much larger develop faster forecast
antolimab efficaci subcutan formul compar iv
formul propos action mast cell provid efficaci subset
patient adequ treat dupix dupix efficaci
overlap asthma atop dermat long list type diseas end
less relev marketplac
what price
street estim model peak antolimab sale price assumpt well
project dupix price eoe annual vs mainten
view antolimab clinic profil
form around leverag insight biolog sialic acid-
bind ig-lik lectin cell surfac protein select express eosinophil mast
cell compani asset antolimab target drive deplet
eosinophil via apoptosi inhibit mast cell activ
multipl agent target eosinophil and/or mast cell across rang
inflammatori condit antolimab differenti mechanist one els
target phase data egid demonstr evid activ proof-of-
concept across rang eg/ege/eo howev far clear differenti
activ eoe largest target market rel agent dupix
surpris given eoe late manifest atop march dupix
gener posit data across categori diseas due central target il-
nevertheless back aforement phase data expect
start phase program eg/eg phase eoe statu
develop across program compani gener data unclear
target indic date antolimab
background egid
eosinophil mast cell pro-inflammatori mediat elev across rang
inflammatori diseas figur includ number gastrointestin indic
character hypereosinophilia high
level eosinophil term eosinophil
indicationu preval addressableaddress populationspecialtylevel gastrogrowingphas gastrolowphas dermhighno updat barclay biopharmaceut
gastrointestin disord egid diseas classifi organ
esophagu stomach duodenum/smal intestin across digest tract
patient develop symptom term egid compris eosinophil esophag
eoe eosinophil gastriti eg eosinophil gastroenter ege
exist unmet need indic given lack approv option beyond oral
steroid suitabl long-term treatment chronic condit
think potenti treatment paradigm commerci opportun upon
introduct research highlight follow point
focu size steroid-refractori popul clinician roughli estim
patient eoe steroid-refractori figur much higher
eg/eg howev impli actual address market
eoe eg/eg
patient symptom beyond egid clinician indic approxim
eoe patient may overlap comorbid asthma atop dermat
critic compet therapi dupix could on-label efficaci
diseas upon label extens eoe could posit well
payor allow insur address multipl diseas cost one drug
antolimab may may offer efficaci diseas well data wont
label
data phase enigma studi antolimab eg/eg demonstr clear proof
concept data view placebo control studi treat patient one two
escal dose scheme iv antolimab max vs
placebo week follow follow-up dose demonstr
signific lower eosinophil eo count irrespect steroid use
improv total symptom score per tss total symptom score
enigma data eg/eg
eg/eg patient enrol also report data set patient
concomit eoe signific percentag
antolimab patient achiev respons defin decreas sever
dysphagia view data encourag evid proof-of-concept
subset studi small one
compar data result gener initi phase studi dupix eoe
patient figur acknowledg up-front caveat cross-trial comparison
overal view data look similar antolimab post higher
respons rate eosinophil deplet vs critic look baselin
eosinophil go studi antolimab baselin less half
dupix arm vs hpf respons defin reduc eosinophil
start lower put one drug advantag reason think
import look percent chang eosinophil point dupix post
reduct eoe studi didnt break specif eosoinophil
reduct eoe cohort like close reduct seen
broader studi small studi pivot agent eoe like
hundr patient point would argu data suggest drug
similar activ eoe
tss respond ivmean chang eo countsmean chang tss barclay biopharmaceut
comparison antolimab enigma eoe cohort dupix phase
eoe eo chang assum compar broader eg/eg studi popul
consid sale potenti antolimab focus follow aspect
indic limit egid compani vocal path forward
egid howev beyond plan strategi larg indic vagu
bar de-risk evid path forward limit analysi egid
administr profil engima studi phase program
use multi-hour iv formul compani on-going phase trial
support develop subcutan inject yet de-risk allako
launch iv formul expect minim uptak eoe particularli sinc
believ dupix and/or agent avail time iv formul
may less issu eg/eg due less competit still think would
limit adopt might otherwis look like
competit largest challeng antolimab commerci success howev
emerg competitor particularli across eoe regeneron sanofi
highlight on-going phase studi could support phase file
studi on-going nucala fasenra arena pharmaceut also
highlight oral inhibitor etrasimod eoe phase data expect next
year mention earlier think agent benefit on-
label efficaci overlap comorbid
price given competit dynam think may challeng
compani launch antolimab charg net annual dupix
explor weekli dose qw phase eoe studi would bring cost
annual dupix regimen also explor differ dose regimen
part studi think like compani shift less frequent dose
week could look first year dupix eoe
follow mainten price could put pressur antolimab
antolimabplacebop-valuedupixentplacebop-valuen steroid use eoesteroid use measuresbaselin eo eo chang w/ w/ w/ sever bl chang sever sdi phase phase barclay biopharmaceut
eg/eg us estim address popul reflect
moderate-to-sever patient inadequate/no respons steroid therapi
assum launch model peak market share repres non-
risk adjust peak sale
eoe market larger patient affect assum similar sever
steroid refractori rate estim biologic-elig patient adult assum
launch model peak market share non-risk adjust peak
sale
togeth model us sale price equival popul
discount orphan price premium current biolog price dupix
eg ege us biolog market dupix otherspati net annual wac annual net sale us eoe us biolog market otherspati net annual net sale us barclay biopharmaceut
subpar share fell vs nbi share ralli much
back posit data august drive share vs
nbi ad almost market cap decemb media report
potenti sale see bloomberg ad anoth market cap sinc data
ytd deal born share appear given back much
takeout premium settl back rang
assign pt share base npv sum-of-the-part analysi
contribut eg/eg lead indic eoe net
cash valuat driven ground-up revenu forecast
estim margin risk-adjust base view probabl success po
eg/eg assign po given de-risk data ahead phase start
assum phase start shortli model file launch
eoe assign po follow earli proof-of-concept data concomit eoe
patient enigma studi wait defin clinic dataset exclud
indic base valuat analysi csu
assign discount rate typic smid-cap development-stag
compani given de-risk data date
 eg/een readoutmedia report explor strateg optionsenigmapresent acg barclay biopharmaceut
risk rate price
risk valuat includ recapitul phase eg/eg data phase
long-term eg/eg data demonstr durabl respons data eoe-onli patient highli
statist signific competitor studi failur acceler biolog use
appli inc quarterli annual ep usd
consensu number bloomberg receiv gmt
initi coverag appli therapeut overweight pt view
appli inhibitor aldos reductas meaning improv potenc
select safeti rel pharma effort recent posit
phase data lead asset galactosemia provid tangibl valid
compani scientif insight ar biolog appli coupl thought
priorit indic leverag use biomark recent fda guidanc
potenti enabl rapid path market next month appli
launch first product read-out phase data diabet
provid line sight first approv monet opportun phase
action data galactosemia rare inherit metabol condit
avail treatment meaning de-risk view given profound reduct
relev metabolit reduct galactitol clean safeti togeth
high unmet need fda guidanc area anticip valu continu accret
program execut toward approv provid line sight
profit open monet opportun partner ou right
sell potenti prv model peak sale base adopt
dbcm underway complet enrol set data
expect one anticip data readout given lack
treatment option address market alon essenti wholly-
own right appli model peak sale conserv cut
address popul reason price expect zero contribut follow-
indic diabet peripher neuropathi retinopathi
valuat risk pt base sum-of-the-part analysi compris
risk-adjust contribut us sale galactosemia at-
dbcm risk includ regulatori approv base singl
clinic trial clinic data dbcm commerci risk around potenti
launch dbcm
initi overweight pt
appli focus biolog aldos reductas ar key enzym
metabol sugar aberr condit pharma keenli focus ar inhibitor
despit sign efficaci ultim abandon space
due liver toxic backdrop appli leverag subsequ advanc x-
ray crystallographi develop differenti better potenc select
lead better efficacy/safeti profil aplt approach support insight
clinic develop regulatori strategi could leav appli posit
one approv drug second clinic de-risk multi-billion-
dollar indic inde posit phase disclos earlier year provid
tangibl evid strategi play assign price target note
impli conservat around read-out posit phase data next year
could see share move well
posit top-lin phase data galactosemia early-januari drove share mid-
said still believ share price probabl
approv given novel regulatori strategi full phase data simd april
affirm regulatori timelin come meet fda
close watch success execut front bring increas attent
commerci side potenti monet opportun ou right prv
phase data read-out set
view far larger opportun given address popul stage
dbcm defin patient view studi higher-risk henc
po given popul heterogen focu endpoint de-risk
phase data could see valuat assign alon move even
consider strateg valu metabol player follow-on indic dpn dr
assign pt base sum-of-the-part sotp analysi compris us
estim galactosemia po dbcm
po assign zero termin valu use discount rate
round whole figur
complet nda within dcm start us total valuat barclay biopharmaceut
monitor thesi track follow catalyst figur
timingev catalystbarclay expectationsapril fda action data simd austin anticip full result action reaffirm biomark data seen top-lin releas anticip approv broad label encompass adult pediatr patient aplt re-affirm regulatori strategi timelin nda submiss phase data support approv dbcm complet pediatr galactosemia studynda submiss galactosemiafda approv top-lin data phase dbcmon schedul fda submiss anticip defin dose emerg pediatr popul barclay biopharmaceut
fda approv base phase data
ye view high probabl phase action galactosemia data adult
demonstr profound reduct aberr metabolit reduct galactitol
evid clinic outcom nevertheless view data combin
well understood pathophysiolog diseas strongli suggest
substrat reduct like predict clinic effect accommod fda
guidanc specif area low-preval rare metabol diseas support
compani regulatori strategi full present action data simd april
provid increment de-risk event urin brain mri data bolster
investor confid data model us file set approv
forecast peak us sale support exist newborn screen
criteria lack altern therapi
reverse-engin model base current share price assum
minim valu assign base ipo price would impli
market price po
brief background galactosemia
oral inhibitor aldos reductas develop galactosemia
rare inborn error metabol galactos specif galactosemia caus
sever defici one two key enzym galk figur lead
disrupt metabol galactos via standard glycolyt pathway instead
galactos convert galactitol cant reduc sorbitol dehydrogenas
instead lead galactitol accumul cell tissu result swell
galactosemia rare inherit condit galactos metabol earli complic
classic galactosemia aris shortli birth without intervent disord
fatal initi galactose-restrict diet revers acut life-threaten
specif display cognit deficit verbal dyspraxia
develop ataxia tremor nearli femal patient experi primari
galactosemia character accumul galactitol glycolyt pathway block
view support preclin clinic data
posit stanc like approv support compel
concord data drug design preclin phase data
specif highlight follow point
penetr brain differenti prior major
effect galactosemia seen neuron brain abil at-
penetr tissu critic demonstr abil
penetr neuron brain also show better potenc much
higher maximum toler dose rel past zopolrestat figur
reduc galactitol level preclin rat model link prevent
deficit learning/motor coordin key part appli narr
ultim allow faster path market next page
develop credibl anim model diseas past anim model fail
recapitul diseas due gener rel low model galactitol key
opinion leader emori univers dr judith fridovich-keil recent develop rat
model deposit larg amount galactitol brain also
shown phenomenon link long-term complic associ
galactosemia importantli upon administr rat galactitol level
could reduc figur long-term complic deficit cognit
abilities/motor coordin could prevent figur
phase studi demonstr substanti consist reduct
galactitol plasma level phase portion action compris three arm singl
dose vs placebo activ arm demonstr
dose-depend reduct galactitol reduct dose
reduct dose plasma patient particularli
encourag tight rang effect galactitol level increment data disclosur
